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ABSTRACT 
 
AKT CONTROLS ADIPOCYTE FUNCTION AND SYSTEMIC METABOLISM 
Abigail L. Shearin 
Morris J. Birnbaum 
 Adipose tissue is a key regulator of energy homeostasis. Diseases with an 
increase or decrease in adiposity result in perturbations of systemic metabolism. The 
insulin signaling and insulin-like growth factor 1 (IGF-1) cascades are vital to the function 
of many tissues during development and in the mature organism. AKT, a Ser/Thr kinase, 
is a central node in the insulin and IGF-1 pathways. In the liver, much is known about the 
consequences when insulin-AKT signaling is lost, but adipose tissue has presented a 
unique challenge to study in vivo. The extant evidence suggests that manipulating the 
insulin-signaling cascade in adipose causes systemic insulin resistance (IR), but often 
these models exhibit a lipodystrophy, implicating insulin/IGF-1 signaling as required for 
adipocyte differentiation or maintenance. In vitro work has identified the insulin pathway 
as necessary for adipocyte differentiation. The mechanism through which adipocyte IR 
causes systemic IR has remained elusive. We used the AdipoQ-Cre to delete Akt1 and 
Akt2 simultaneously (Adipo-AKT KO) and individually (Adipo-AKT1 KO, Adipo-AKT2 KO) 
to understand how loss of AKT signaling affects the mature adipocyte. Adipo-AKT KO 
mice have a severe lipodystrophy with hyperinsulinemia, hepatosteatosis, and perturbed 
glucose homeostasis. Adipo-AKT1 KO mice have no obvious defects, but Adipo-AKT2 
KO mice have systemic IR, with hyperinsulinemia, elevated free fatty acids (FFAs), and 
blunted insulin-stimulated glucose uptake in adipocytes. This defect has been proposed 
to account for the observed IR in models with loss of adipocyte insulin signaling, 
supported by work using the aP2-Cre to delete glucose transporter 4 (aP2-Glut4 KO), 
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the insulin-responsive glucose transporter, but subsequent work has shown the aP2-Cre 
is not adipocyte-specific. We tested this mechanism by generating mice with AdipoQ-Cre 
deletion of Glut4 (Adipo-Glut4 KO). These mice do not have systemic IR, unlike the aP2-
Glut4 KO. We conclude that loss of adipocyte glucose uptake cannot account for the IR 
in the Adipo-AKT2 KO, and that the most likely candidate for the propagation of IR from 
the adipocyte to the liver is elevated FFAs, which promote hepatic glucose production. 
We propose that loss of AKT2 causes elevated FFAs because of blunted suppression of 
lipolysis in response to insulin.  
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PREFACE 
 
Adipose tissue, once considered inert, is now known to include a multitude of cell 
types, including immune cells, vascular and perivascular cells, neuronal cells, adipocyte 
precursors, and mature adipocytes. It is, consequently, the focus of increasing scientific 
interest, particularly relating to how new adipocytes are generated, how they change in 
response in stimuli, how they function in the mature state, and how they impact the body 
systemically. Adipose tissue is now considered central to the maintenance of energy 
homeostasis, which has led to an improved understanding of both lipodystrophic 
disorders and obesity. Lipodystrophic and obese patients have likewise benefited greatly 
from the knowledge gained in studies of adipocytes, particularly as regulators of glucose, 
fatty acids, and adipokines. Our understanding of the important of adipokines has 
especially improved the treatment of lipodystrophic individuals as they often have 
dramatically decreased levels, especially of leptin. Some clinical success has been 
achieved in treating these patients with leptin replacement therapy. 
Lipodystrophic patients and models have led to a greater appreciation for the 
requirement of healthy, functional adipose tissue to maintain systemic homeostasis, 
informing our knowledge of the opposite end of the adiposity spectrum, obesity. Those 
with a severe lipodystrophy exhibit many of the same physiological ailments that affect 
patients with insulin resistance (IR) and Type 2 diabetes mellitus (T2DM), such as 
hepatosteatosis and hyperinsulinemia, though often leptin levels are elevated in obese 
patients and they can exhibit leptin resistance as well as insulin resistance. How obesity 
predisposes to IR and T2DM is not well defined, but improving our understanding of how 
insulin resistant adipose tissue affects whole body energy homeostasis is imperative to 
intervening in these disease states. Several mechanisms have been proposed, but this 
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work has been hampered by the difficulty of specifically targeting adipocytes in vivo, and 
because manipulating the insulin signaling pathway in an attempt to cause IR often 
leads to lipodystrophic models, with little to no adipose tissue available for study and 
severe systemic dysfunction. However, from this work and in vitro studies, we have 
learned that many potential factors made, stored, or secreted by adipose tissue play a 
role in how adipocytes are altered in the insulin resistant state and why that dysfunction 
affects the overall health of the organism.  
 
  
 
1	  
	  
CHAPTER 1: 
 
General Introduction 
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1.1 Canonical insulin signaling  
Overview of the insulin signaling cascade 
 In the adult organism, insulin and insulin-like growth factor-1 (IGF-1) are 
essential for homeostasis. Insulin and IGF-1 have many actions in every tissue and cell 
type of the body, but insulin, and IGF-1 to a less extent, are especially crucial in organs 
responsible for the maintenance of energy balance: brain, liver, muscle, and adipose 
(Rask-Madsen and Kahn, 2012). Activation of the insulin or IGF-1 receptor initiates a 
complex cellular cascade that, while similar in broad terms, is distinct in each tissue. 
Here we focus largely on the adipocyte, with insulin regulating anabolism via 
downstream targets common to all tissues, and also glucose uptake and suppression of 
lipolysis (Figure 1-1). In the fasted state, circulating insulin levels are low and the tissues 
are in the basal state. During a meal, insulin is released from beta cells in the pancreas 
in response to glucose, fatty acids, and other factors (Rorsman and Braun, 2013). In all 
of these tissues, insulin binds to its receptor (IR) on the cell surface, activating several 
kinases including the Grb2-associated-binder-1 (Gab1) and the insulin receptor 
substrates (IRS) 1 and 2, which are activated by IR in a relatively specific manner by 
recruiting the receptor via the pleckstrin homology (PH) and phosphotyrosine binding 
(PTB) domain (Farhang-Fallah et al., 2002; Taniguchi et al., 2006). IRS1/2 is able to 
bind a number of proteins, including Grb2, which activates the cell growth pathway Ras-
mitogen-activated-protein kinase (Ras-MAPK), but the climacteric kinase activated by 
IRS1/2 is phosphotidylinositol (3,4,5)-kinase (PI3K) (Rask-Madsen and Kahn, 2012; 
Taniguchi et al., 2006). The Ras-MAPK pathway, regulated by Grb2 downstream of 
IRS1/2, is coordinately regulated with the PI3K pathway to control cell growth and 
differentiation, ultimately activating extracellular-signal regulated kinase (ERK), which 
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regulates transcription factors critical fro cell growth and proliferation and p90 ribosomal 
S6K, an integral kinase for protein synthesis (Avruch, 1998; Mendoza et al., 2011). PI3K 
is a family of kinases, with classes I, II, and III having separate functions and 
physiological implications that are further explored below (Thorpe et al., 2015).  
PI3K I is the isoform stimulated by insulin and other growth factors and involved 
in the regulation of propagating these signals throughout the cell (Thorpe et al., 2015). 
Once activated, PI3K phosphorylates the inositol ring of phosphatidylinositol (4,5) 
bisphosphate to phosphotidylinositol (3,4,5) triphosphate (PIP3), which subsequently 
initiates a cascade of serine/threonine kinase activity, directly recruiting 
phosphoinositide-dependent kinase 1 (PDK1) and its substrate AKT/PKB, among others, 
to the cell membrane (Dibble and Cantley, 2015). PDK1 phosphorylates AKT at Thr308, 
but maximal activation of AKT, a central ser/thr kinase in the insulin signaling cascade, 
also requires phosphorylation at Ser473 by the mechanistic target of rapamycin complex 
2 (mTORC2) (Sarbassov et al., 2005). AKT represents a central node in the insulin 
signaling cascade, with multiple, separate pathways downstream controlling various cell 
processes (Figure 1-1).  
 
AKT activity promotes anabolism and suppresses catabolism 
Akt has three isoforms with each isoform encoded by a distinct gene and 
expression differentially regulated during time points of development and in adult tissues 
(Dummler and Hemmings, 2007). Akt1 is ubiquitously expressed in all tissues of the 
body and is most critical during development and cellular proliferation (Walker et al., 
1998). Akt3 is more highly expressed in the brain, though the specific regions in which it 
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is most active and its neurological function remains elusive (Easton et al., 2005; Walker 
et al., 1998). In the insulin-responsive tissues of adult organisms acutely regulated by 
insulin: liver, muscle, and adipose, Akt2 is the predominantly expressed isoform 
(Altomare et al., 1995; 1998). Akt1 is expressed in these tissues as well, but at lower 
levels (Walker et al., 1998). Downstream of AKT, the insulin signaling cascade becomes 
specific to cell-type, dependent on the obligatory functions of the tissue. Well-established 
direct substrates of AKT include the transcription factor forkhead box O (FOXO), the 
tuberous sclerosis complex (TSC1/2) complex--a GTPase activating protein for Rheb, 
proline-rich substrate 40 (PRAS40)—a protein associated with the mechanistic target of 
rapamycin complex 1 (mTORC1), and the Rab GTPase activating protein 
AS160/TBC1D4 that regulates glucose transport (Dibble and Cantley, 2015; Siddle, 
2011). Canonically, AKT directly regulates insulin-mediated suppression of lipolysis in 
adipocytes via phosphorylation of phosphodiesterase 3B, but an AKT-independent 
pathway has also been identified (Choi et al., 2010; DiPilato et al., 2015).  
 
FOXO 
FOXO, DAF-16 in C. elegans, was identified as being downstream of the insulin 
receptor like gene (DAF-2), PI3K (AGE1) and AKT from a genetic screen of dauer larvae 
(Gottlieb and Ruvkun, 1994; Lin et al., 1997; Ogg et al., 1997; Paradis and Ruvkun, 
1998; Riddle et al., 1981). Since its identification as a pivotal member of the insulin 
signaling cascade, FOXO has been heavily studied. In mammals, there are 4 FOXO 
family members, 1, 3a or 3, 4, and 6. Foxo6 is expressed most highly in neurons, but the 
three other isoforms are more ubiquitious, with Foxo1 being essential for life, Foxo3 
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deletion leading to developmental defects, and Foxo4 deletion causing no obvious 
defects (Paik et al., 2007). In the adult animal, FOXO1 (termed FOXO here) is regulated 
by both AKT phosphorylation and acetylation by Sirtuin 1 (Sirt1), and histone 
deacytelases (HDACs) (Frescas et al., 2005; Mihaylova et al., 2011). Active, nuclear 
FOXO is not phosphorylated and most lines of evidence suggest a lack of acetylation is 
also important for maximal FOXO activity, though acetylation by HDAC appears to 
positively regulate FOXO (Mihaylova et al., 2011). Several other mechanisms may exist 
that regulate FOXO activity on some level; evidence suggests XBP-1 in the unfolded 
protein response indirectly regulates FOXO and PGC-1a may also induce glycosylation 
(Housley et al., 2009; Y. Zhou et al., 2011).  
Upon stimulation of AKT, FOXO is phosphorylated at Thr24 and becomes 
excluded from the nucleus (Matsuzaki et al., 2003). As a transcription factor active in the 
fasting state, FOXO promotes the expression of genes necessary for development and 
in the adult maintenance of energy balance in an insulin-poor state (Matsumoto et al., 
2006; Tikhanovich et al., 2013). Conservation of FOXO targets is also observed, with 
1659 targets shared between the mouse and C. elegans (Webb et al., 2016). In the liver, 
where FOXO functions in the adult mammal are the most thoroughly studied, it promotes 
expression of gluconeogenic genes such as glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK) (W. Zhang et al., 2006). Mice that 
overexpress FOXO have increased gluconeogenesis, while mice without hepatic FOXO 
develop fasting hypoglycemia (Matsumoto et al., 2006; 2007). In mice without hepatic 
IR-AKT signaling, gluconeogenesis is unrestrained and deleting FOXO simultaneously 
corrects this (Dong et al., 2006; 2008; Lu et al., 2012; Titchenell et al., 2015).  
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While FOXO’s regulation of gluconeogenic genes is well-established, how it 
regulates genes involved in lipid synthesis and fatty acid oxidation is less clear. In mice 
without hepatic Foxo1 and Foxo3a, hepatic lipid content was increased, but serum 
triglycerides were decreased (K. Zhang et al., 2012). The authors also showed 
decreases in fatty acid synthase (FAS), a key enzyme in DNL, and HMG CoA reductase, 
the committed enzyme in fatty acid oxidation (K. Zhang et al., 2012). Increased FOXO 
activity in the liver causes reduced expression of key lipogenic genes such as sterol 
regulatory element binding protein 1c (SREBP1c), acetyl-CoA carboxylase (ACC) and 
fatty acid synthase (FAS) (W. Zhang et al., 2006). This is consistent with decreases in 
the expression of these genes in mice lacking AKT in the liver (Titchenell et al., 2016). A 
role for FOXO in the regulation of liver albumin production has also been described; 
mice without hepatic AKT or IR and active FOXO suppress albumin production, but 
concomitant deletion rescues the hypoalbuminemia (Q. Chen et al., 2016). 
In muscle, active FOXO downstream of decreased AKT signaling causing 
atrophy in cultured mytobules through elevated atrogin-1, a muscle-specific ubiquitin-
ligase, expression, and decreased FOXO induction leading to downregulation of atrogin-
1 transcript levels (Sandri et al., 2004). Recent work has found similar results in vivo, 
with deletion of insulin receptor and insulin-growth factor-1 receptor in the muscle 
resulting in nuclear accumulation of active FOXO and upregulation of both atrophy and 
autophagy genetic programs. Subsequent deletion of FOXO in this model rescues the 
atrophy of muscle mass (O'Neill et al., 2016). The role of FOXO in mature adipose tissue 
has been poorly described, though its role in adipocyte differentiation is better 
understood and is discussed in the below section on insulin signaling in the adipocyte. 
Overexpression of a dominant negative FOXO restricted to the adipocyte in vivo causes 
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improvement in glucose tolerance and insulin sensitivity, potentially as a result of the 
observed increased energy expenditure (Nakae et al., 2008). 
 
mTORC1  
 Within the context of insulin signaling, the primary directive of tuberous sclerosis 
complex 1/2 is the suppression of mTORC1 activity without insulin, and the 
permissiveness of mTORC1 activity in response to insulin. In the basal, or fasted, state, 
TSC1/2 is maintained at the lysosome in a GDP-bound Rheb-dependent manner, 
preventing mTORC1 association of the Rheb and the lysosome (Menon et al., 2014). In 
response to enagement of the insulin receptor and subsequent signaling events, 
including AKT phosphorylation of TSC complex at multiple sites, TSC1/2 is released 
from Rheb and the lysosome, allowing mTORC1 to bind to GTP-bound RHeb and be 
activated (Menon et al., 2014). PRAS40 becomes dissociated from mTORC1 in 
response to insulin, allowing for substrate binding (L. Wang et al., 2007). Amino acids, 
mainly leucine and arginine, are also able to activate mTORC1 in an insulin-independent 
manner. The mechanism for leucine’s promotion of mTORC1 activity was recently 
elucidated to depend on relief of suppression of Rag guanine triphosphatases (GTPs) 
through a Sestrin2-GATOR2-dependent pathway (Wolfson et al., 2016). Sestrin2-
GATOR2 suppress mTORC1 activity and upon binding of leucine, this complex is 
disrupted and inhibition of Rag is alleviated, allowing for the stimulation of mTORC1 
(Budanov and Karin, 2008; Wolfson et al., 2016). CASTOR, or cellular arginine sensor 
for mTORC1, also interacts with GATOR2 in a manner similar to Sestrin1 and 
dissociates when stimulated by arginine (Chantranupong et al., 2016). 
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Once mTORC1 activity is induced, it is a driving force of anabolism in the cell as 
a vital member of several pathways for synthesis of macromolecules, proteins, lipids, 
and nucleic acids (Howell et al., 2013). mTORC1 can acutely initiate protein synthesis 
via phosphorylation of eukaryotic-initiation factor 4-E binding proteins (4EBPs), 
weakening it’s interaction with eukaryotic initiation factor (eIF), and allowing the 
assemblage of the eIF4F translation initiation complex (X. M. Ma and Blenis, 2009). S6 
kinase (S6K) is also a key substrate of mTORC1; S6K phosphorylates a number 
proteins in the translation initiation complex, including the ribosomal protein S6, eIF4B, 
and eEF2k (Raught et al., 2004; X. Wang et al., 2001). Additionally, mTORC1 promotes 
overall translation through the induction of ribosomal biogenesis also through 
phospohorylation of 4-EPB1/2, which translation 5’-terminal oligopyrimidine tracts (5’-
TOP) mRNAs (Thoreen et al., 2012).   
Lipid synthesis is also regulated by mTORC1 in an sterol-regulatory element 
binding protein 1 and 2 (SREBP)-dependent manner (Düvel et al., 2010; Porstmann et 
al., 2008). SREBPs are responsible for the transcriptional regulation of a large 
percentage of the lipogeneic program (Horton et al., 2002; 2003), and mTORC1 is 
necessary for the processing of cellular SREBP to nuclear SREBP, a cleavage step that 
requires SREBP cleavage-activating protein (SCAP) (Sun et al., 2007). SREBP1 is also 
involved in the production of genes for the pentose-phosphate pathway (PPP), a salvage 
pathway for ribose and a critical cellular source for de novo synthesis of purines 
(Stincone et al., 2015). Via S6K, mTORC1 is also involved in the de novo synthesis of 
pyrimidines (Ben-Sahra et al., 2013; Robitaille et al., 2013). Recent studies in adipose 
tissue have highlighted mTORC1’s role in the beiging of inguinal fat, identifying β-
adrenergic, PKA-dependent signaling as another source of mTORC1 regulation (D. Liu 
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et al., 2016; Tran et al., 2016). Other labs, however, did not observe the same loss in the 
ability of adipose depots lacking raptor to beige (P. L. Lee et al., 2016). mTORC1 may 
also play a role in the adipose tissue to stimulate lipolysis, which is discussed in more 
detail below. This brief synopsis of the many functions of mTORC1 within the cell 
underscores its incredible importance in the propagation of the insulin signal for 
anabolism, cellular maintenance, growth, and overall energy homeostasis.  
 
AS160 
 AS160, or AKT substrate 160kD, also termed TBC1D1, is a Rab-GAP protein 
that is required for maximal insulin-stimulated glucose uptake and is directly 
phosphorylated by AKT at multiple sites in response to insulin receptor activation 
(Lansey et al., 2012; Sano et al., 2003). Phosphorylation of AS160 is also stimulated by 
muscle contraction in an AMPK-depdent manner (Kramer et al., 2006). As a Rab-GAP 
protein, it activates small GTPases at the Glut4 storage vesicle (GSV) along with 
another Rab-GAP, the Ral-GAP complex (RGC) (X.-W. Chen et al., 2011; Leto and 
Saltiel, 2012). AS160 is active in the basal, fasted state, maintaining Glut4 and the GSV 
in insulin-poor conditions; it is deactivated by AKT2 phosphorylation, permitting Glut4 to 
translocate to the plasma membrane (Sano et al., 2003). In fact, when AS160 is 
depleted from 3T3L1 adipocytes, Glut4 is redistributed to the plasma membrane in basal 
conditions and GSV exocytosis is reduced in response to insulin (Eguez et al., 2005). 
When AS160 is overexpressed, Rab proteins are inactive and Glut4 translocation in 
response to insulin is blunted (Sano et al., 2003). AS160 is required for maximal insulin-
stimulated GSV exocytosis, but is dispensable for GSV endocytosis, suggesting that the 
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mechanisms related to external trafficking are distinct from those regulating recycling of 
the GSV (Zeigerer et al., 2004). Mice null for AS160 have a defect in insulin-stimulated 
glucose uptake into both the muscle and adipose tissue. These mice have elevated 
transcript levels of glucneogenic enzymes in the liver and at age 16 weeks have a 
blunted response to insulin injection (Lansey et al., 2012; H. Y. Wang et al., 2013).  
 
1.2 Insulin action is required for adipocyte differentiation and maintenance 
Adipocyte differentiation  
Adipocytes have a mesenchymal stem cell origin that becomes committed to an 
adipocyte precursor state through the integration of physical characteristics of the extra 
cellular matrix and WNT signaling (Cristancho and Lazar, 2011). The progression of this 
committed precursor to a mature adipocyte is intensely regulated by multiple signaling 
events in the bone morphogenetic protein (BMP) and CCAAT/enhancer-binding protein 
(C/EBP) pathways, among others (Cristancho and Lazar, 2011). As differentiation 
progresses, other factors become critical, most notably peroxisome proliferator-activated 
receptor y (PPARy), which is both required and sufficient to induce adipogensis 
(Cristancho and Lazar, 2011; Lazar, 2005). While adipogenesis occurs prenatally, it is 
more prominent in the first few days postnatal, with rapid expansion of adipose depots in 
the neonate (Kirtland and Harris, 1980). This expansion of adiposity is attributed to 
increased nutrient intake, consistent with in vitro studies showing that insulin signaling is 
required for adipogenesis. Studies performed in mouse embryonic fibroblasts (MEFs) 
and NIH 3T3L1 cells has shown that loss of AKT, a central node in the insulin signaling 
cascade, inhibits adipogenesis (Nakae et al., 2000; Yun et al., 2008; 2009).  
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AKT is required for adipogenesis 
AKT, a ser/thr kinase downstream of the insulin receptor and phosphotidyl-
inositol-3 kinase, is regulated during all states of adipogenesis. In precursor cells, the 
Akt1 isoform is the most highly expressed (Altomare et al., 1998; Walker et al., 1998). 
This isoform is ubiquitous in the organism and is particularly critical during development. 
Akt2, the isoform most highly expressed in insulin responsive tissues, especially 
adipocytes, muscle, and liver, is not as critical during development and is not highly 
expressed in adipocyte precursors (Altomare et al., 1998). MEFs isolated from mice null 
for Akt1 exhibit defective adipocyte differentiation, while MEFs from Akt2 null mice have 
normal differentiation (Yun et al., 2009; 2008). This is further expanded upon by MEFs 
from embryos null for both Akt1 and Akt2 successfully differentiating when AKT1 is 
replaced but not when AKT2 alone is replaced (Yun et al., 2008). However, this is 
inconsistent with in vivo data. Given the in vitro data, one would expect Akt1 null mice to 
exhibit a lipodystrophy resulting from impaired adipogenesis. While these mice have an 
overall smaller body size and are protected from diet-induced obesity, potentially as 
result of increased energy expenditure, they do not have a change in their adiposity as 
percent of body weight (Cho et al., 2001; Wan et al., 2011a). This suggests that the in 
vivo milieu and potentially compensation from AKT2 allows for adipogenesis to progress. 
As expected from the in vitro data, mice null for Akt2 do not have a decrease in adiposity 
as adults, but exhibit a mild lipodystrophy when aged, the cause of which is unknown 
(Cho, 2001; Garofalo et al., 2003). While mice lacking Akt1 and Akt2 in the germline die 
shortly after birth, if they are rescued, they exhibit many defects, one of which is 
impeded adipocyte development in vivo (Peng et al., 2003).  
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FOXO inactivation is required for adipogenesis 
The mechanistic role of insulin action and active AKT in adipogenesis is 
proposed to be the suppression of FOXO activity (Nakae et al., 2008; 2003; Yun et al., 
2008). FOXO (Forkhead bOX-containing protein, subfamily O), has four isoforms, 1, 3a, 
4, and 6 and is a critical transcription factor during both development and in mature 
tissues (Accili and Arden, 2004). FOXO6 is not a substrate of AKT, while the other three 
isoforms are regulated by AKT (Accili and Arden, 2004). All three of these FOXO 
isoforms are expressed in mature adipocytes, but FOXO1 is the most highly expressed 
in all depots (Nakae et al., 2003). Knockdown of AKT in 3T3L1 cells leads to active Foxo 
and an inhibition of adipocyte differentiation. Overexpression of constitutively active 
FOXO1, that cannot be phosphorylated by AKT, has similar effects, with no observed 
adipocyte differentiation (Nakae et al., 2003).  
 
Insulin signaling is required for adipocyte maintenance 
How the adipocyte is maintained is largely unanswered in the field because of 
the challenges of targeting the mature adipocyte until recent years. With the 
development of a Cre recombinase transgene driven by the Adiponectin promoter, 
AdipoQ-Cre, we are better able to target mature adipocytes, but this also has its 
caveats. The inguinal adipose depot expresses adiponectin at levels sufficient to induce 
Cre expression during development, but the epididymal depot does not have embryonic 
expression of adiponectin (Hong et al., 2015). The precursors studied in the adult 
animal, in both inguinal and epididymal depots do not express AdipoQ-Cre (Berry and 
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Rodeheffer, 2013). How the expression of AdipoQ-Cre in the inguinal depot during 
embryogenesis affects adipogenesis at later time points and in the adult is unknown. 
The expression profile of adiponectin in developing brown adipose tissue (BAT) is also 
unknown.  
Work from multiple labs have targeted factors required for adipocyte 
differentiation with the AdipoQ-Cre and suggest that these factors are also required for 
adipocyte maintenance. The loss of adipocyte PPARy causes a severe lipodystrophy 
with very little adipose tissue, hepatosteatosis, and hyperinsulinemia (F. Wang et al., 
2013). Based on current information regarding the timing of Cre expression, it is 
reasonable to interpret that the loss of the epididymal fat tissue is a defect in 
maintenance, while inguinal adipose may never develop and the BAT is unknown at this 
time. The loss of the insulin receptor in the adipocyte also causes a lipodystrophy with 
insulin resistance, though these mice have more adipose tissue than what is observed in 
the PPARy mice (Qiang et al., 2016). The loss of both insulin receptor and insulin like 
growth factor-1 receptor (IGF-1R) leads to a profound lipodystrophy, both with the use of 
the congenital AdipoQ-Cre and when induced through use of the AdipoQ-CreER that 
requires tamoxifen injection for Cre expression and recombination of the floxed alleles 
(Boucher et al., 2016; Softic et al., 2016). This strongly suggests that insulin receptor 
and IGF-1R are required for maintenance, though a confounding variable is that 
tamoxifen alone can induce adipocyte loss followed by adipogenesis, leading to a 
transient lipodystrophy, which is observed in the insulin receptor/IGF-1R knockout 
adipose tissue: upon withdrawal of the tamoxifen, the adipocytes regenerate (Boucher et 
al., 2016; Softic et al., 2016; Ye et al., 2015).  
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1.3 β-adrenergic and insulin signaling regulate lipolysis in adipocytes 
Stimulation of lipolysis during the fasting state  
Adipose has long been described as a site of energy storage, but it’s importance 
in the regulation of energy availability and the processes through which energy is stored 
and released only began to generate interest in the past few decades (Rosen and 
Spiegelman, 2014). The adipocyte provides energy to other tissues during the insulin-
poor fasting state and replenishes those stores in the insulin-replete fed state. In the 
fasted state, adipose tissue undergoes lipolysis, the breakdown of triglyceride into fatty 
acids and glycerol to supply energy to metabolically active organs, such as the liver, 
muscle, brain, and heart (Duncan et al., 2007). In the fasted state in the absence of 
insulin and nutrient intake, lipolysis is upregulated through B-adrenergic signaling, 
activating adenylate cyclase and promoting cyclic AMP production, thereby activating 
protein kinase A (PKA) via PDK1, a ser/thr kinase that stimulates lipolysis by 
phosphorylating and activating several lipases (Cheng et al., 1998). The key enzymes 
involved in lipolysis have multiple points of regulation, especially through Perilipin, which 
is phosphorylated directly by PKA at several residues required for maximal activation, 
including ser497 and ser522 (H. H. Zhang et al., 2003).  
 
Perilipin 
Perilipin has two established functions in the regulation of lipolysis. Un-
phosphorylated Perilipin binds to the lipid droplet and protects it from cellular lipases, 
making it a critical element in the preservation of lipid stores in the adipocyte (Tansey et 
al., 2001). Phosphorylated Perlipin stimulates lipolysis in two ways, the first by allowing 
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lipases access to the lipid droplet, and the second by releasing comparative gene 
identification-58 (CGI-58), a cofactor for adipocyte triglyceride lipase (ATGL) that Perlipin 
binds in the insulin-poor state and is also phosphorylated directly by PKA (Lass et al., 
2006; Sahu-Osen et al., 2015; Yamaguchi et al., 2004; 2007). CGI-58 enhances 
activation of ATGL, the initiating step of lipolysis, hydrolysis of triglyceride of 
diacylglycerol (Lass et al., 2006). PKA directly phosphorylates both ATGL and hormone-
sensitivie lipase (HSL) (Krintel et al., 2009; Pagnon et al., 2012). HSL is required for the 
hydrolysis of diacylglycerol to monoacylglycerol, but it is also able to hydrolyze 
triglyceride to diacylglycerol (Kraemer and Shen, 2002). Upon phosophorylation, HSL 
translocates from the cytoplasm to the lipid droplet (McDonough et al., 2011). Recent 
work has suggested that adipocyte AMP-activated protein kinase (AMPK) is also critical 
to the phosphorylation and activity of ATGL and HSL, providing another layer of 
regulation to the maintenance of lipolysis in the nutrient-poor state (S.-J. Kim et al., 
2016). 
Perilipin null mice have the expected phenotype of a decrease in adiposity, 
consistent with perilipin functioning to protect the lipid droplet from cellular lipases 
(Tansey et al., 2001). Additionally, without adipose Perilipin, CGI-58 is likely readily 
available to co-activiate ATGL, further increasing lipolysis. These mice have elevated 
basal lipolysis, but Perilipin null adipocytes have a blunted response to isoproterenol, a 
similar phenotype to that observed in AMPK adipocyte knockout mice (S.-J. Kim et al., 
2016). Despite their decreased adiposity and inability to store lipids in the liver, these 
mice are glucose intolerant. Surprisingly, mice over-expressing adipocyte Perlipin also 
have a decrease in adiposity, but are protected from diet-induced obesity, exhibit low 
basal lipolysis, and are protected from diet-induced glucose intolerance and insulin 
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resistance (Miyoshi et al., 2010). While the perlipin null and overexpressing mice have 
dramatic phenotypes, the downstream lipases regulated by Perilipin are also critical for 
regulating adiposity and insulin sensitivity.  
 
Adipose triglyceride lipase and hormone sensitive lipase 
Deactivation of perlipin and release of CGI-58 is required for maximal ATGL 
activity, but ATGL it is also phosphorylated directly by PKA at Ser406. This 
phosphorylation event is required for maximal ATGL activity, and constitutively 
phosphorylated ATGL-Ser406 has increased basal lipolytic activity (Pagnon et al., 2012). 
In vitro work has postulated that ATGL transcriptional expression is regulated by the 
canonical insulin signaling cascade, with FOXO stimulated expression during the basal 
state and mTORC1 suppressing expression via the transcription factor early growth 
factor 1 (Egr-1) in the insulin-stimulated state (Chakrabarti and Kandror, 2009; 
Chakrabarti et al., 2013). Currently, we do not know if these processes occur in vivo, but 
whole-body deletion of Atgl does result in systemic changes. Atgl null mice on low fat 
diet (LFD) have increased adipose accumulation, but improved insulin sensitivity; this is 
more evident when control and ATGL null mice are fed high fat diet (HFD) for four weeks 
(Hoy et al., 2011). The control mice become insulin and glucose intolerant, while the 
ATGL -/- mice maintain insulin sensitivity and glucose tolerance similar to what is 
obeserved in LFD fed ATGL null mice. Both LFD and HFD fed ATGL -/- mice have 
reduced circulating free fatty acid levels (FFAs) and on HFD they exhibit reduced plasma 
insulin levels compared to control mice. The adipose tissue is likely driving this 
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phenotype, as adipocyte-specific ATGL deletion reveals a similar phenotype with 
protection from diet-induced insulin resistance (Schoiswohl et al., 2015).  
HSL is phosphorylated directly by PKA at multiple sites, with Ser660 and Ser659 
controlling HSL activity. It has been proposed that phosphorylation at these sites 
promotes a conformational change in the HSL protein, allowing it to interact with tri- or 
di- acylglycerol (Krintel et al., 2009). Mice null for hormone-sensitive lipase do not have a 
change in overall fat mass on normal chow or HFD, though diacylglycerol has been 
shown to accumulate in the WAT of this model without an increase in adiposity 
(Haemmerle et al., 2002; Park et al., 2005b). These mice have decreased plasma FFAs 
and when fed normal chow, improved hepatic insulin sensitivity. On HFD, HSL -/- mice 
have improved WAT and muscle glucose uptake compared to HFD-fed controls mice 
(Park et al., 2005b). Haploinsufficiency of HSL results in reduced lipolytic capability, and 
improved insulin sensitivity without gross abnormalities in adipose depot mass (Girousse 
et al., 2013). Taken together, these studies suggest a link between a loss of lipolytic 
activity and improved systemic insulin sensitivity, especially when challenged with diet-
induced obesity.  
 
Insulin-mediated suppression of lipolysis 
In response to insulin, following a meal, Perilipin, HSL, and ATGL are 
dephosphorylated and lipase activity and access to the lipid droplet is sharply decreased 
(Carmen and Víctor, 2006). The regulation of this process by insulin action likely 
includes both AKT-dependent and AKT-independent, PI3K-dependent mechanisms 
(Choi et al., 2010). Previous work has shown in 3T3L1 cells that insulin-mediated 
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suppression of lipolysis, stimulated by isoproterenol, was incomplete but present when 
AKT inhibitor was added to the cells, suggesting that an AKT-independent mechanism is 
able to partially suppress lipolysis.  This study went on to use wortmannin to 
pharmalogically inhibit PI3K, and insulin action in 3T3L1 cells to suppress lipolysis was 
ablated (Choi et al., 2010). Several studies have suggested that AKT-dependent 
suppression of lipolysis functions through phosphodiesterase 3B (PDE3B), whereby AKT 
phosphorylation of PDE3B is required to activate the phosphodiesterase, hydrolyzing 
cAMP and returning it to basal levels, leading to the suppression of perlipin and lipase 
activity (Carmen and Víctor, 2006; Snyder et al., 2005). However, other work has 
suggested that the AKT phosphorylation site on PDE3B is dispensable for insulin’s 
suppression of lipolysis (DiPilato et al., 2015).  
In vivo work has further suggested an AKT-independent mechanism for insulin 
action to suppress lipolysis. In mature insulin-responsive tissues, Akt2 is the most 
prevalent isoform of Akt expressed (Altomare et al., 1998). The Akt2 null mouse has mild 
defects in the ability to suppress lipolysis, with slight but significant increases in plasma 
glycerol and FFAs levels in response to an insulin tolerance test, but lipolysis is 
suppressed when compared to the fasting state. However, decreases in insulin 
sensitivity in the adipocyte may be the result of systemic insulin resistance in this model 
and not the result of adipocyte-autonomous insulin resistance (Koren et al., 2015).  
 
1.4 Insulin-stimulated glucose uptake in myocytes and adipocytes 
In contrast to lipolysis, insulin-stimulated glucose uptake in adipocytes is, based 
on current knowledge, AKT-dependent. To replenish the energy stores depleted during 
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fasting to maintain in vivo homeostasis, the adipocyte takes up energy in the fed state. It 
does this in the form of glucose and fatty acids. These building blocks are used to 
generate triglycerides through re-esterification and glucose is also used as a carbon 
source for de novo lipogenesis (Solinas et al., 2015). 
 
Trafficking of Glut4 to the plasma membrane 
Insulin-stimulated glucose uptake in adipocytes and myocytes is mediated at the 
most distal level by glucose transporter 4 (Glut4). When insulin is released from β-cells 
and engages the insulin receptor on adipocytes and myocytes, a tightly regulated 
cascade is initiated that includes the activation of AKT, which then phosphorylates and 
inactivates the Rab-GTPases AS160 and RGC at the glucose storage vesicle (GSV) of 
the cell, where Glut4 is sequestered. One of the Rab proteins involved in this pathway 
has been identified as Rab10, which is associated with GSVs and appears to target its 
associated GSVs to the plasma membrane in response to insulin. The trafficking of 
GSVs to the plasma membrane in this As160-Rab10-dependent pathway functions 
through the myosin motor protein myosin-Va (Y. Chen et al., 2012). Rab10 may also be 
involved in the recycling of Glut4 through endosomes, and may even target some 
endosomes for the plasma membrane to further increase glucose uptake under 
prolonged insulin exposure (Y. Chen et al., 2012). Tumour suppressor candidate 5 
(Tusc5) has also been shown to regulate Glut4 recycling back to the plasma membrane 
from endosome under conditions of continuous insulin stimulation and may represent a 
PPARy mechanism for regulating mature adipocyte function (Beaton et al., 2015). 
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The suppression of the Rab-GTPases and Rab10-targeted GSV translocation is 
coordinately regulated with an AS160-independent mechanism for translocation of Glut4 
to the plasma membrane in response to insulin. An essential member of this trafficking 
pathway has been identified as a protein termed TUG (tether, containing a UBX domain, 
for Glut4) (Bogan et al., 2003).  TUG tethers GSVs intracellulary, most likely to the trans-
golgi network (TGN), in the basal state (Bogan et al., 2012). In response to insulin, TUG 
is cleaved, liberating the tethered GSV to allow trafficking to the plasma membrane. 
Knockdown of TUG in 3T3L1 adipocytes prevents maximal insulin-stimulated glucose 
uptake (Bogan et al., 2012). Interestingly, knockdown of TUG in unstimulated 3T3L1 
adipocytes elicits an exocytosis of GSVs similar to that observed in wild-type insulin-
stimulated cells (Xu et al., 2011). It is not yet established if the TUG-dependent 
trafficking of Glut4 also requires AKT function.  
At the cell membrane, the Rho-family small GTPase TC10, assembles the GSV 
to the membrane in an PI3K-independent, insulin, APS-dependent, process (Chiang et 
al., 2001; J. Hu et al., 2003). The active insulin receptor recruits the adaptor protein 
APS, which is expressed in skeletal muscle, heart, and adipose tissue, organs with high 
rates of glucose uptake in response to insulin (Ahmed et al., 1999; Moodie et al., 1999). 
APS activation by IR recruits a complex containing c-Cbl, a member of the Cbl family of 
E3-ubiquitin ligases, and facilitates phosphorylation of c-CBL to allow recruitment of the 
adaptor protein, proto-oncogene CRK and the guanine-exchange factor (GEF) C3G  (J. 
Liu et al., 2002; Ribon et al., 1996). C3G then phosphorylates TC10 that is located on 
lipid rafts in the plasma membrane and initiates interaction between the membrane and 
GSVs (Chiang et al., 2001; Knudsen et al., 1994).  
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AKT2 is required for glucose uptake 
The pathways regulating glucose uptake converge at the cell membrane, but 
both are required for glucose uptake to occur. Manipulating glucose uptake downstream 
at the level Glut4 or TC10 ablates glucose uptake as efficiently as manipulating 
upstream effectors, such as AKT, AS160, or Rab10 (Bae et al., 2003; Cho, 2001; 
Lansey et al., 2012; Vazirani et al., 2016; H. Y. Wang et al., 2013). In vitro data strongly 
implicate AKT2 as the isoform most efficient at regulating insulin-responsive glucose 
uptake and both in vitro and in vivo work as suggested that AKT2 is required for maximal 
glucose uptake (Bae et al., 2003; Cho, 2001; Gonzalez and McGraw, 2009a; 2009b).  
The Akt2 null mouse exhibits defects in insulin-stimulated glucose uptake in both 
adipocytes and myocytes, the two tissues most dependent on Glut4 translocation for 
active glucose uptake (Bae et al., 2003; Cho, 2001). These mice are insulin resistant, as 
are mice with muscle-specific deletion of Glut4 and mice with aP2-Cre mediated deletion 
of Glut4, suggesting that at least from a muscle and whole-body perspective, loss of 
insulin-stimulated glucose uptake alone may be sufficient to cause systemic insulin 
resistance (Abel et al., 2001; Cho, 2001; Zisman et al., 2000). In contrast. AKT1 is 
dispensable for glucose uptake in vitro and in vivo, as the Akt1 null mouse does not 
have defects in glucose uptake (Bae et al., 2003; Cho et al., 2001). Loss of both Akt1 
and Akt2 in the germline results in a loss of adipogenesis (Peng et al., 2003). 
 
1.5 Insulin and glucose stimulate de novo lipogenesis in adipocytes 
 In response to insulin in the fed state, adipocytes take up glucose and free fatty 
acids, undergoing re-esterification to replenish their triglyceride stores that were 
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depleted in the fasted state. However, some of the carbons from glucose are diverted to 
de novo lipogenesis (DNL) (Herman et al., 2013; Marcelino et al., 2013; Solinas et al., 
2015). During adipocyte differentiation, DNL, measured by supplying radio-labeled 
glucose and glutamine tracers but no exogenous sources of fatty acids, is sufficient for 
production of all lipids necessary to differentiate and accumulate normal lipid droplets 
(Collins et al., 2011). In humans, the contribution of DNL to total triglyceride 
accumulation in adipocytes has been calculated to be ~20%, representing an important 
source of triglycerides (Strawford et al., 2004). Rates of DNL are influenced by diet as 
well, with diets high in glucose promoting DNL and diets high in triglycerides suppressing 
DNL (Hudgins et al., 2008; Lambert et al., 2021). Adipocytes with high rates of DNL tend 
to be smaller in size and are associated in vivo with insulin sensitivity, as opposed to 
adipocytes with lower rates of DNL that are larger in size and associated with insulin 
resistance, in contrast to our understanding of DNL in the liver being highly correlated 
with insulin resistance (Eissing et al., 2013; Lambert et al., 2021; Postic and Girard, 
2008; Roberts et al., 2009). This dichotomy remains true when manipulating the DNL 
cascade in the liver versus adipocytes. When carbodhydrate response element binding 
protein (ChREBP), a critical regulator of DNL in both tissues, is knocked down in the 
liver it improves insulin sensitivity, but decreased expression of ChREBP in the 
adipocyte is correlated with reduced insulin sensitivity (Dentin et al., 2006; Herman et al., 
2013). SREBP, a key target of mTORC1 signaling, also regulates the expression of DNL 
genes in both adipose and hepatic tissues (Shimano et al., 1999).  
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ChREBP and SREBP1c 
 ChREBP has been shown to be responsive to glucose concentration 
independent of insulin stimulation in hepatocytes and stimulates target DNL genes 
acetyl-CoA carboxylase (ACC), ATP-citrate lyase (ACL), and fatty acid synthase (FAS), 
the rate-limiting step of de novo lipogenesis (Iizuka et al., 2004; Yamashita et al., 2001). 
Germline deletion of ChREBP results in mice unable to undergo lipogenesis in their liver, 
glucose intolerance, and insulin resistance (Iizuka et al., 2004). Interestingly, when Glut4 
is over-expressed exclusively in the adipocyte in the ChREBP null mouse, an 
improvement in glucose tolerance is observed (Herman et al., 2013). Additionally, when 
stressed on a high fat diet (HFD), mice over-expressing adipose Glut4 are protected 
from insulin resistance and glucose intolerance, with a partial rescue in the DNL genetic 
program (Herman et al., 2013). These data isolate glucose signaling and ChREBP 
expression, specifically the isoform identified in this work, ChREBPB, in the adipose 
tissue as the fundamental regulators of DNL in the adipocyte. Furthermore, it implies that 
loss of ChREBP in the adipocyte causes insulin resistance that can be partially rescued 
by increased glucose uptake.  
In mice null for SREBP, many of the downstream targets that are co-regulated by 
ChREBP and SREBP were decreased, including ACC, FAS and ACL in both adipose 
and liver (Shimano et al., 1999). However, SREBP expression of these genes in adipose 
specifically may be less important than the regulation of ChREBP, as several studies 
have suggested that loss of ChREBP expression affects the downstream targets, but 
does not affect expression of SREBP (Herman et al., 2013; Tang et al., 2016). This does 
not rule out that processing of SREBP to its nuclear form by an SREBP cleavage-
activating protein (SCAP)-mediated process has decreased function in these models, 
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and thus it cannot be ruled out that SREBP is indeed an important regulator that has 
been overlooked. More is known about SREBP regulation in the liver, discussed in more 
detail below.  
 
1.6 Adipose tissue as an endocrine organ 
 Since the discovery of leptin in 1997 as a hormone produced in adipose tissue 
and distributed systemically, most importantly to the brain to regulate satiety, the 
function of adipose tissue as an endocrine organ has been intensely studied (Kershaw 
and Flier, 2004; Waki and Tontonoz, 2007). Other adipocytokines, or adipokines, also 
play key roles in regulating satiety and insulin sensitivity.  
 
Adiponectin 
Adiponectin is produced exclusively by adipose tissue and plays an important 
role in systemic sensitivity to insulin (E. Hu et al., 1996). Mice null for adiponectin have a 
mild insulin resistant phenotype in some studies, while others do not find a systemic 
effect with loss of adiponectin function in the mouse (K. Ma et al., 2002; Maeda et al., 
2002; Nawrocki, 2005). Several studies have correlated low adiponectin levels to insulin 
resistance in both mouse models of genetic or diet-induced obesity, a primate model of 
T2DM, and in insulin resistant humans (Hotta et al., 2001; E. Hu et al., 1996; Kadowaki 
et al., 2006; Nawrocki, 2005; Weyer et al., 2001). Elevated adiponectin levels in mice 
expressing an active adiponectin transgene are more insulin sensitive than control mice 
(Combs et al., 2004). The mechanism underlying adiponectin’s insulin-sensitizing effect 
is believed to be largely due to regulation of AMP-protein kinase (AMPK) in the liver, 
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potentially by reducing the expression of gluconeogenic enzymes and thereby activating 
AMPK (Berg et al., 2001; Combs et al., 2004; Yamauchi et al., 2002).  
 
Resistin 
Another adipokine, resistin is associated with both insulin resistance and 
inflammation, and some studies have suggested it inhibits adipocyte differentiation 
(Holcomb et al., 2000; K. H. Kim et al., 2001; Steppan et al., 2001). Mice injected with 
resistin develop glucose intolerance and insulin resistance, and it was postulated to be a 
target of action for thiazolidnediones (TZDs) that induce PPARy action and improve 
insulin sensitivity (Steppan et al., 2001). However, other studies have suggested that 
resistin expression is suppressed in obese and insulin resistant states, with activation of 
PPARy using TZDs inducing resistin expression and contributing to the insulin-
sensitizing effects of TZD administration (Way et al., 2001). Still other studies have 
argued there is a disconnect between the mRNA expression of resistin in diabetes 
versus circulating levels, which may explain the difference between the studies 
performed (Rajala et al., 2004). Higher circulating levels of resistin has been correlated 
with obesity in human studies (Degawa-Yamauchi et al., 2003; Kusminski et al., 2005). 
Recent work has replicated the original data showing that giving exogenous resistin to 
mice decreases insulin sensitivity, and this work also suggests that resistin plays a role 
in regulation of blood pressure, potentially through a Toll-like receptor 4-dependent 
mechanism (Jiang et al., 2016). Interestingly, resistin is expressed predominantly by 
adipocytes in mice, but by macrophages in humans, and also by other tissues (Patel et 
al., 2003; Savage et al., 2001). Mice expressing human resistin in a macrophage-
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specific manner were insulin resistant and had increased resistin expression in WAT 
after only 4 days of being fed a HFD, and further increased after 3 weeks, providing 
evidence for macrophage infilitration into WAT during HFD feeding (Qatanani et al., 
2009).  
 
Leptin 
Leptin, arguably the most famous adipokine, is an anorexegenic hormone, 
regulating energy balance by suppressing food intake, leptin levels are increased in 
obese individuals (Klok et al., 2007). This observation led to the discovery of leptin 
resistance during obesity (Bjørbaek et al., 1998; Dietrich et al., 2008). Mice without leptin 
(ob/ob) or the leptin receptor (db/db), were originally identified in 1950 and 1966, 
respectively (Hummel et al., 1966; INGALLS et al., 1950). These mice have been 
studied for more than half a century, but it wasn’t until the 1990s that leptin was 
identified as the “obese” gene encoding the circulating factor lacking in ob/ob mice and 
the receptor lacking in db/db mice (Tartaglia et al., 1995; F. Zhang et al., 1997). The 
discovery and study of leptin has resulted in a field of neuronal leptin signaling and more 
broadly, the central nervous system regulation of obesity and energy homeostasis. Loss 
of plasma leptin is associated with a constellation of physiologic consequences, 
including hyperphagia, insulin resistance as a result of hyperphagia, and decreased 
energy expenditure. Several models of lipodystrophy have been treated with leptin and 
rescued their insulin resistance (W. S. Chen et al., 2009; CortEs et al., 2014; Gray et al., 
2006; Shimomura et al., 1999). Still other studies have suggested that Type I diabetes 
mellitus (T1DM) can be successfully treated with leptin, arguing that models of T1DM 
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have hypoleptinemia resulting in increased activity of the hypothalamic-pituitary axis and 
leading to increased lipolysis and hepatic insulin resistance (Perry et al., 2014). In obese 
patients with elevated leptin levels and leptin resistance, a leptin sensitizer has recently 
shown promise in inducing weight loss (J. Lee et al., 2016).  
Leptin and other adipose-cytokines, or adipokines, have identified an endocrine 
adipose-brain axis not previously understood. Adipokines are part and parcel of the vital 
function of adipose tissue in the maintenance of overall organismal health and energy 
balance.  
 
1.7 Lipodystrophy leads to systemic insulin resistance 
In lipodystrophy patients, a lack, or severe decrease, of adipose tissue 
dramatically disrupts overall energy homeostasis, leading to many hallmarks of insulin 
resistance and Type 2 Diabetes Mellitus (T2DM), but without the presence of obesity 
(Garg, 2004). Congenital generalized lipodystrophy (CGL) Type 1 is the most common 
form of lipodystrophy occurring in humans and results from a mutation in the 1-
acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2) gene (Agarwal et al., 2002; 
Garg, 2004). Germline knockout of Agpat2 causes a lipoatrophy, as or more severe than 
when the gene responsible for CGL Type 2, Seipin, is deleted in a whole-body or 
adipose-specific manner (CortEs et al., 2009; Cui et al., 2011; L. Liu et al., 2014). Other 
genes have been implicated in human lipodytrophic conditions as well, including, in the 
insulin-signaling pathway, AKT2 and a subunit of PI3K (Chudasama et al., 2013; Garg, 
2004; George, 2004; Magré et al., 2001; Savage et al., 2003; Wojtanik et al., 2009).  
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Several other mouse models exhibit profound lipodystrophic phenotypes, most 
notably the AZIP/F-1 dominant negative mouse which is unable to induce adipocyte 
development but has been used to study adipocyte development by transplanting the 
stromal vascular fraction and observing which cells develop into adipocytes (Moitra et 
al., 1998; Rodeheffer et al., 2008). These models, and others, all exhibit a similar 
phenotype, with non-alcoholic fatty liver disease (NAFLD), hyperinsulinemia, and often 
hyperglycemia. Some models have elevated circulating FFAs as well, but others do not, 
likely due to their severe lack of adipose tissue and an inability to increase FFAs in 
response to a fast (Colombo et al., 2003; CortEs et al., 2009; Cui et al., 2011; L. Liu et 
al., 2014; Moitra et al., 1998). In lipodystrophic patients and mouse models, several 
hallmarks of insulin resistance are present and have informed our understanding of the 
fundamental role that adipose tissue plays in maintaining energy balance. The severity 
of these IR signs may be increased in lipodystrophy compared to obese patients and 
models, but their inability to appropriately regulate adipocyte function may also point to 
critical players in how obese individuals also fail to maintain their systemic homeostasis. 
 
1.8 Obesity, insulin resistance, and Type 2 diabetes mellitus 
Overnutrition and obesity are a rising epidemic, now a leading risk factor for the 
worldwide disease burden (Haslam and James, 2005). Obesity is correlated with a 
constellation of physiologic disturbances including hypertension, high cholesterol, fasting 
hyperinsulinemia, hyperglycemia and glucose intolerance, with an estimated annual cost 
of over $209 billion (Cawley and Meyerhoefer, 2012; Sims et al., 1973). How obesity and 
overnutrition affect tightly regulated energy homeostasis is poorly understood. In 
vertebrates, adipose tissue, classified as a connective tissue, is now recognized as a 
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central organ in the regulation of energy. Our ability to intervene in the epidemic of 
obesity and its sequelae requires a greater understanding of how adipose tissue 
regulates energy homeostasis. 
Twenty-nine million people in the United States have Type 2 diabetes, and nearly 
three times as many are “prediabetic,” both defined by fasting plasma glucose levels, 
increased hemoglobin A1C (HbA1C) levels, an indicator of glucose levels over the 
previous 3 months, and an oral glucose tolerance test (8944, 2015; Prevention, 2015). In 
prediabetes some inability to regulate hyperglycemia is observed, with elevated HbA1C, 
and fasting blood glucose concentration over 100 mg/dL (8944, 2015). Prediabetes is 
much more common than full-fledged diabetes, and even before developing prediabetes, 
individuals are insulin resistant. In an insulin resistant state, glucose levels are 
maintained by overcoming the systemic insulin resistance in metabolic organs by 
secreting more insulin. For reasons that are unclear, weight loss and increased physical 
activity improve overall insulin sensitivity (8944, 2015). Furthermore, it is not well 
understood how diet and/or physiological impacts of hyperinsulinemia and 
hyperglycemia affect the metabolic changes observed in insulin-responsive tissues. For 
example, we only recently understand how de novo lipogenesis in the liver contributes to 
non-alcoholic fatty liver disease (Lambert et al., 2021). Information garnered from the 
use of insulin-sensitizing therapeutics, such as the TZD family of drugs, suggests that an 
increase in adiposity does not necessarily equate to decreased insulin sensitivity, but 
rather that efficiently sequestering fatty acids into adipocytes can improve systemic 
insulin responsiveness (Lehrke and Lazar, 2005).  
Correlation between insulin resistance and a defect in suppression of lipolysis in 
adipose tissue has been observed in humans, and in dogs a link between FFAs and 
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hepatic insulin responsiveness has been reported (Girousse et al., 2013; Moore et al., 
2004; Rebrin et al., 1996; Sindelar et al., 1996). The peripheral regulation of HGP has 
recently garnered additional support from work done in rodents (Perry et al., 2015; 
Titchenell et al., 2016). This work has proposed that FFAs-driven HGP as a result of 
adipose insulin resistance is responsible for the what has been termed “selective insulin 
resistance,” referring to the paradox of why, in the insulin resistance state, the liver 
remains sensitive to insulin to promote DNL and triglyceride accumulation, resulting in 
NAFLD, but is insensitive to insulin in regards to suppression of HGP, causing 
hyperglycemia in the face of high insulin levels (Brown and Goldstein, 2008). Potentially, 
HGP is regulated independently of liver insulin signaling and in response to adipose 
insulin signaling. These data suggest that adipose tissue may be elemental to our 
understanding of the pathology of obesity and T2DM in humans, but only recently have 
the tools become available to pursue these studies in an adipocyte-centered manner in 
vivo. 
 
1.9 Challenges in targeting adipose tissue in vivo 
In vivo regulation of the adipocyte response to insulin has, until very recent 
years, been an intractable question due to a lack of tools for targeting adipose tissue 
specifically.  Historically, models attempting to delete elements of the insulin-signaling 
cascade in adipocytes were generated using Cre recombinase driven by the aP2 
promoter (Abel et al., 2001; Blüher et al., 2002; Boucher et al., 2012; Kumar et al., 
2010). Interpretation of the genetic models published with the aP2-Cre is confounded by 
its promiscuous expression, demonstrated by subsequent work showing that aP2-Cre is 
expressed in muscle, liver, and brain, all important regulators of insulin sensitivity (K. Y. 
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Lee et al., 2013; Mullican et al., 2013). Additionally, the aP2-Cre is expressed in 
adipocyte precursors, and at least in one study, is shown to stochastically express in 
cells during development, perhaps accounting for the expression in multiple organs 
(Berry and Rodeheffer, 2013; K. Y. Lee et al., 2013). A more adipocyte-specific Cre was 
generated by the Rosen lab, using the Adiponectin promoter to drive Cre recombinase 
expression (AdipoQ-Cre) (Eguchi et al., 2011). With an improved ability to target the 
adipocyte in a tissue-specific manner, a number of studies have reported on the 
consequence of deletion of elements of the insulin signaling cascade in the adipocyte, 
as well as other critical regulators of adipocyte function (Boucher et al., 2016; P. L. Lee 
et al., 2016; Mottillo et al., 2016; Owen et al., 2012; Softic et al., 2016; Tang et al., 2016; 
Vazirani et al., 2016; F. Wang et al., 2013).  
 
1.10 Adipocyte insulin resistance as the causal event in systemic insulin 
resistance 
Since the development of the AdipoQ-Cre for adipocyte-specific recombination of 
floxed alleles, several studies have examined the effects of losing various members of 
the insulin signaling cascade in the adipocyte. Manipulation of some of these 
components have resulted in a lipodystrophy. Adipocyte loss of the insulin receptor (IR) 
alone leads to approximately a 50% loss of overall fat tissue, while loss of both IR and 
insulin-growth factor 1 receptor (IGF-1R) simultaneously lead to a severe lipodystrophy 
(Boucher et al., 2016; P. L. Lee et al., 2016; Softic et al., 2016). Mice with an inability to 
maintain adipose-depot stores have profound changes in their systemic physiology, 
exhibiting similar effects as human patients with lipodystrophy (Garg, 2004). However, 
when downstream factors in the insulin signaling cascade are targets, mild lipodystrophy 
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phenotypes are observed with surprisingly profound affects on insulin sensitivity. For 
example, ablation of the mTORC1’s function, though the deletion of the mTORC1-
specific component raptor, also leads to a progressive lipodystrophy with insulin 
intolerance, suggesting that mTORC1 might be a critical downstream target of insulin 
signaling in the maintenance of adipose tissue (P. L. Lee et al., 2016; D. Liu et al., 
2016). This could the result of a defect in mTORC1’s ability regulate lipolysis, potentially 
through Atgl, as has been suggested by in vitro data (Chakrabarti et al., 2013). 
Alternatively, insulin resistance and a progressive lipodsytrophy is also seen when rictor, 
an mTORC2 specific component, is deleted in the adipocyte (Tang et al., 2016). This 
model also exhibits defects in glucose uptake, regulation of de novo lipogenesis, and an 
inability to fully suppress lipolysis in response to insulin (Tang et al., 2016).  
Previous work published using the aP2-Cre showed that loss of Glut4 also led to 
systemic insulin resistance and defects in de novo lipogenesis, but this work has not be 
replicated with the AdipoQ-Cre (Abel et al., 2001). More recently, Rab10 has been 
deleted in an adipocyte-specific manner with the AdipoQ-Cre, effectively ablating 
glucose uptake in the adipocyte, and causing hepatic insulin resistance, but maintaining 
adipocyte and myocyte insulin sensitivity (Vazirani et al., 2016). Taken together, these 
studies suggest that loss of effective insulin signaling in the adipocyte is sufficient to 
cause some level of systemic insulin resistance, but it remains unclear which function of 
the adipocyte is most critical for the expansion of insulin resistance to the other 
metabolic organs, glucose uptake or regulation of free fatty acid levels.  
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1.11 AKT is required for systemic insulin sensitivity 
Germ-line deletion of the insulin receptor is not compatible with life, but tissue-
specific deletion of IR in the liver, muscle, and adipose tissue has informed our 
understanding of the requirement for insulin signaling to maintain energy balance 
(Biddinger et al., 2008; Boucher et al., 2016; O'Neill et al., 2016; 2015; Qiang et al., 
2016; Softic et al., 2016). Insulin-receptor substrate 2 is required for insulin sensitivity, 
but insulin-receptor substrate 1 is not (Previs et al., 2000; Withers et al., 1998). The loss 
of various subunits of PI3K, including p110a and p110b, p85a and p85b have suggested 
a nuanced regulation of insulin signaling via PI3K, with loss of p85a and p85b, activators 
of PI3K yielding more insulin sensitive phenotypes with increased Akt phosphorylation 
(Brachmann et al., 2005; Zhao et al., 2006). These data suggest that in addition to PI3K 
propagating downstream insulin signaling, it coordinately regulates suppression of the 
cascade. The protein phosphatase and tensin homologue (PTEN) is a phosphatase 
integral to downregulating the insulin signaling cascade, reverses the actions of PI3K 
(Leslie and Downes, 2004). When deleted in adipocytes in an inducible manner, these 
mice gain more weight than their control littermates on short-term HFD, but have 
improved glucose and insulin tolerance, as well decreased fasting insulin levels (Morley 
et al., 2015). This may be due to the increased AKT signaling observed when the mice 
are on HFD (Morley et al., 2015). Germ-line deletion of both Akt1 and Akt2 concurrently 
is incompatible with life beyond birth, unless intense care is provided to the neonates, 
similar to germ-line deletion of IR, but mice null for either isoform are viable (Cho, 2001; 
Cho et al., 2001; Peng et al., 2003). Akt1 -/- mice have a smaller overall body size, but 
have no other overt defects, with normal adiposity and insulin sensitivity (Cho et al., 
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2001). In contrast, mice without AKT2 are insulin resistance, with defects in suppression 
of hepatic glucose production and glucose uptake in muscles and adipocytes (Cho, 
2001; Garofalo et al., 2003). Later work also described an inability to completely 
suppress circulating fatty acids and glycerol in this model during hyperinsulinemic-
euglycemic clamp and in response to an insulin bolus (Koren et al., 2015). While this 
model informs our understanding of the requirement for AKT2 to maintain insulin 
sensitivity, it does not tell us which tissues are contributing to the insulin resistance. 
Further studies have been performed with liver-specific deletion of Akt2 and Akt1, Akt2 
together (Leavens et al., 2009; Lu et al., 2012; Titchenell et al., 2016; Wan et al., 2013; 
2011b). 
 
Hepatic insulin resistance is sufficient to cause systemic insulin resistance 
Manipulation of insulin signaling in the liver has been shown in several studies to 
cause autonomous defects in insulin signaling and peripheral insulin resistance 
(Biddinger et al., 2008; Dong et al., 2006; Leavens et al., 2009; Lu et al., 2012; Titchenell 
et al., 2015; Wan et al., 2013). Congenital deletion of IR in the liver causes a severe 
hepatic and physiologic insulin resistance. Similarly, loss of hepatocyte Akt2 using a Cre 
transgene driven by the promoter for alpha-fetoprotein (AFP) also results in both hepatic 
and systemic insulin resistance (Leavens et al., 2009; Wan et al., 2013; 2011b). These 
mice have defects in their suppression of hepatic glucose production in response to 
insulin, blunted glucose disposal, decreased glycogen deposition, and a reduction in 
hepatic triglyceride content resulting from an inability to perform de novo lipogenesis 
(Leavens et al., 2009; Wan et al., 2011b). Surprisingly, while phosphorylation of AKT is 
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blunted in response to insulin in these mice, phosphorylation of Foxo is maintained, 
while PRAS40 phosphorylation is deficient (Leavens et al., 2009).  
 
AKT control of HGP is dependent on suppression of FOXO 
The loss of Akt2 in an acute setting, using an AAV-TBG-Cre system to induce 
recombination of the Akt2 floxed allele, does not have a profound an effect on hepatic or 
systemic insulin sensitivity (Lu et al., 2012). It is only when Akt1 and Akt2 are both 
acutely deleted in the hepatocyte that a severe insulin resistance is induced (Lu et al., 
2012; Perry et al., 2015; Titchenell et al., 2016). This model has an inability to suppress 
hepatic glucose production (HGP) during a hyperinsulinemic-euglycemic clamp and has 
blunted glucose disposal. Lu, et al (2012) reported that concomitant deletion of Foxo 
with Akt1 and Akt2 rescued the liver’s response to insulin, suppressing HGP without 
canonical insulin signaling (Lu et al., 2012). Additional evidence for this was provided by 
Titchenell, et al (2015) with deletion of hepatic IR or IR and Foxo simultaneously 
(Titchenell et al., 2015). Mice with acutely deleted IR exhibited a phenotype similar to 
that observed with congenital deletion, and loss of FOXO showed a similar improvement 
as observed in the Akt1/Akt2/Foxo liver deletion model, suggesting that in the context of 
regulation of HGP, the ultimate purpose of insulin is to suppress FOXO activity (Lu et al., 
2012; Titchenell et al., 2015).   
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Suppression of Foxo and activation of mTORC1 are both required for hepatic de novo 
lipogenesis 
As Leavens, et al (2009) established, AKT2 signaling is required for hepatic de 
novo lipogenesis and this model exhibits a decrease in hepatic triglyceride accumulation 
(Leavens et al., 2009). The studies of FOXO requirement for HGP did not address the 
affect deletion of hepatic FOXO has on triglyceride accumulation or de novo lipogenesis. 
Indeed, mice with acute loss of hepatic IR or AKT1/AKT2 are unable to accumulate 
triglyceride in their livers and subsequent deletion of Foxo does not rescue this defect. It 
is well established that AKT also regulates tuberous sclerosis complex 1/2 (TSC1/2) 
complex, which is paramount in the regulation of mTORC1. In the fasted state, without 
AKT signaling, TSC1/2 is active and keeps mTORC1 function suppressed (Manning and 
Cantley, 2003). When the insulin receptor is engaged and AKT becomes active, TSC1/2 
action is reduced and is permissive to mTORC1 activity (Manning and Cantley, 2003). 
Thus, when Akt is deleted from the cell, TSC1/2 is constitutively active and mTORC1 is 
never maximally functional. mTORC1 is known to be integral to de novo lipogenesis 
(DNL). It is required for cleavage of SREBP1c to the nSREBP1c, allowing this 
transcription factor to enter the nucleus and induce expression of the DNL program 
(Quinn and Birnbaum, 2012). A distinct mechanism for ChREBP regulation in response 
to insulin is currently unclear. However, when Akt1/Akt2/TSC1/2 hepatocyte knockout 
mice were generated, DNL is not rescued (Titchenell et al., 2016). Only when all four 
alleles, Akt1/Akt2/TSC1/2/Foxo, are deleted, is DNL restored. Through some unknown 
mechanism, active FOXO, which is present in the Akt1/Akt2/TSC1/2 mouse, is able to 
suppress DNL (Titchenell et al., 2016).  
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Circulating FFAs as the cause of hepatic insulin resistance 
Multiple models with loss of insulin components specifically in the liver have 
shown a defect in whole body glucose uptake on hyperinsulinemic-euglycemic clamp, 
suggesting muscle insulin resistance, and most likely adipose tissue as well. Muscle 
takes up approximately 90% of all glucose that disappears during a hyperinsulinemic-
euglycemic clamp, while adipose and liver are responsible for the remainder (Kraegen et 
al., 1985). For this reason, Rd is not particularly informative for establishing adipocyte 
insulin resistance. Instead, deducing insulin’s ability to suppress lipolysis by measuring 
circulating free fatty acids (FFAs) and glycerol is a more direct method of determining 
adipose IR. When insulin signaling is lost specifically in the liver, circulating FFAs and 
glycerol are elevated compared to control mice in response to insulin, suggesting a 
defect in adipocyte insulin sensitivity (Perry et al., 2015; Titchenell et al., 2016). 
Additionally, when higher doses of insulin are given during a clamp study and FFAs 
levels are suppressed, HGP is suppressed in mice without AKT1 and AKT2 in the liver. 
Furthermore, when triglyceride levels are replaced under these conditions, HGP is no 
longer able to be suppressed in response to insulin, strongly implicating elevated 
circulating FFAs as the cause of the hepatic insulin resistance (Titchenell et al., 2016). 
While this model suggests that loss hepatic insulin signaling as the inciting event is 
sufficient to cause adipose insulin resistance, and that disruption of adipose insulin 
signaling is not required, it provides convincing evidence that FFAs can promote HGP 
when hepatic insulin signaling is ablated.  
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1.12 Concluding Remarks 
The mechanisms that promote systemic insulin resistance, and ultimately T2DM, 
remain incompletely defined, with each new study providing additional information in the 
complex pathogenesis of this disease. Our understanding of how the liver responds to 
insulin and the necessary elements of the pathway for regulation of gluconeogenesis 
and DNL has developed dramatically in recent decades. However, the contribution of 
adipose tissue IR to T2DM is still relatively unknown. Many data conflict and/or offer 
potential contributing, but partial, regulation of various mechanisms through which 
adipose may affect systemic insulin sensitivity. The model of blunted glucose uptake in 
adipose tissue and downstream defects in DNL largely being responsible for the 
adipocyte’s contribution to insulin resistance has prevailed, but both historic and more 
recent studies have suggested this story is incomplete. While many of the manipulations 
of insulin signaling in the adipocyte have been confounded by a dramatic loss of adipose 
mass, still others identify multiple defects in adipocyte function that may account for the 
observed effects on the whole body. In attempt to circumvent the lipodystrophies 
observed in mice with loss of various components of insulin signaling, inducible models 
have been made for the insulin receptor and IGF-1R (Boucher et al., 2016; Softic et al., 
2016). Unfortunately, these also result in a lipodystrophy. Ultimately, what is needed to 
better address this issue, is a detailed understanding of the downstream mechanisms in 
adipocytes with perturbed insulin signaling, and the components of the cascade that are 
disrupted leading to systemic insulin resistance. When this is established, targeting that 
component exclusively would preserve the mechanisms for adipogenesis and lipid 
production, likely segregating the lipodystrophy from the insulin resistance. 
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In the experiments described below, we ask if adipocyte AKT is required for 
adipocyte function, the maintenance of energy balance, and systemic insulin sensitivity. 
We show that simultaneous loss of both AKT1 and AKT2 results in a severe 
lipodystrophy, suggesting that AKT is required in vivo for adipocyte maintenance. We 
show that AKT2, but not AKT1, is required for both adipocyte function and systemic 
insulin sensitivity. Additionally, we provide evidence that the loss of adipocyte insulin-
stimulated glucose uptake is not the mechanism driving insulin resistance in mice 
lacking adipocyte AKT2.  
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Figure 1-1. The insulin signaling cascade 
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CHAPTER 2: 
 
Lack of AKT in adipocytes causes severe lipodystrophy 
(Shearin et al., 2016) 
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Introduction 
 Adipose tissue functions as a repository for long-term energy storage and as a 
critical regulator of energy balance, satiety, glucose metabolism and other physiological 
processes. White adipose tissue (WAT) stores and releases fatty acids and glycerol in 
response to the energetic need of the organism, whereas brown adipose tissue (BAT) 
produces heat to maintain thermostasis upon cold-exposure. Lipodystrophy is a disease 
characterized by lack of adipose tissue accompanied by metabolic derangements. The 
most common form of lipodystrophy is congenital generalized lipodystrophy (CGL), 
which affects approximately one in ten million individuals and is characterized by a near 
complete absence of adipose tissue (Garg, 2004). CGL Type 1 is caused by mutations 
in 1-acylglycerol-3-phosophate O-acyltransferase 2 (AGPAT2) (Agarwal et al., 2002; 
Garg, 2004) and mice null for Agpat2 exhibit a complete lipoatrophy (CortEs et al., 
2009). Mutations in Seipin cause CGL Type 2, or Berardinelli-Seip congential 
lipodystrophy type 2 (BSCL2), and mice null for Bscl2/Seipin, or with adipose-tissue 
specific loss, are also lipodystrophic, (Cui et al., 2011; L. Liu et al., 2014). Several 
additional genes have been implicated in CGL and familial partial lipodystrophy, 
including Akt2 and a subunit of phosphatidylinositol 3 kinase (PI3K) (Chudasama et al., 
2013; Garg, 2004; George, 2004; Magré et al., 2001; Savage et al., 2003; Wojtanik et 
al., 2009). Hepatomegaly from fatty liver and splenomegaly are common in 
lipodystrophic patients, with hyperinsulinemia and hypertriglyceridemia often present.  
AKT, a Ser/Thr kinase, is activated upon engagement of the insulin receptor and 
mediates hormonal regulation of many aspects of energy homeostasis in insulin-
responsive tissues, including adipose tissue. AKT can also be activated by insulin 
growth factor 1 (IGF-1) (Alessi et al., 1996; Walsh et al., 2002; Zheng and Quirion, 
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2006). Three isoforms of AKT have been identified, of which AKT1 and AKT2 account 
for the majority of AKT in adipocytes (Altomare et al., 1998; Walker et al., 1998). AKT1 is 
expressed nearly ubiquitously and is critical in the control of growth, while the AKT2 
isoform is expressed predominantly in the adult insulin-responsive tissues, including 
liver, muscle, and adipose. Mice lacking Akt2 are insulin-resistant (Cho, 2001), but 
spared from severe metabolic abnormalities due to compensation by Akt1 (W. S. Chen 
et al., 2009; Fischer-Posovszky et al., 2012; Peng et al., 2003).  
In this study, we deleted Akt1 and Akt2 selectively in adipocytes of mice, thus 
interrupting a critical insulin signaling pathway. We found that loss of these AKT isoforms 
in adipocytes caused profound lipodystrophy, associated with fatty liver and systemic 
insulin resistance.   
 
Results 
 
Loss of AKT1 and AKT2 in adipocytes causes lipodystrophy 
To determine the role of AKT in regulating adipocyte function and survival, we 
generated mice lacking both Akt1 and Akt2 using the AdipoQ-Cre driver (Eguchi et al., 
2011). Adipo-AKT knockout (KO) mice were severely lipodystrophic at 8-12 weeks of 
age such that all subcutaneous and cutaneous fat depots, including interscapular brown 
adipose tissue, were completely absent (Figure 2-1A).  The epididymal WAT was about 
10x smaller (as a percentage of body weight) in Adipo-AKT KO mice as compared to 
control mice (Figure 2-1B).   Hematoxylin and Eosin staining of tissue sections showed 
that the residual epididymal WAT (eWAT) in KO mice contained a modest number of 
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enlarged adipocytes (Figure 2-1C). The KO eWAT also displayed increased infiltration of 
F4/80+ macrophages (Figure 2-1D). The levels of important adipokines, such as leptin, 
adiponectin, and resistin, were dramatically decreased in Adipo-AKT KO mice relative to 
controls (Figure 2-1E). The body weight of Adipo-AKT KO mice was increased about 
15% by 5 weeks of age, with controls weighing ~17.3g and Adipo-AKT KO mice 
weighing ~20.5g (Figure 2-1F). This increase in body weight was maintained at 9 weeks 
of age with control mice weighing ~21.8g and Adipo-AKT KO mice weighing ~26.0g. 
These results show that AKT is required for the maintenance of adipose tissues (Figure 
2-1F). 
 
Hepatomegaly 
Adipo-AKT KO mice had livers weighing 2.7 times that of control animals when 
normalized for body weight at 8-12 weeks of age.  Livers in Adipo-AKT mice constituted 
13% of body weight, and were 3.5g on average, as compared to 4.9% of body weight, 
about 1g, in controls (Figure 2-2A, B). The greater size of KO livers was associated with 
a large increase in liver triglyceride levels.  Control mice had an average of 9.2 mg 
triglyceride/g of liver whereas Adipo-AKT KO livers had 169.1 mg triglyceride/g of liver 
(Figure 2-2C). Histopathological analysis of livers from Adipo-AKT KO mice revealed a 
disorganized morphology with an increase in both the number and size of lipid droplets 
(Figure 2-2D).  
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Organomegaly 
 In addition to hepatomegaly, the Adipo-AKT KO mice displayed enlarged 
pancreases and kidneys (Figure 2-3A). On the other hand, Adipo-AKT KO mice did not 
exhibit splenomegaly, which is often associated with lipodystrophy (Garg, 2004; 
LAWRENCE, 1946; Misra and Garg, 2003; ZIEGLER, 1928) (Figure 2-3A).  
Histopathology of both the spleen and kidney revealed no obvious abnormalities (Figure 
2-3B, C). In contrast, the pancreases of KO mice had enlarged islets (Figure 2-3D). 
 
Glucose homeostasis 
We next assessed glucose homeostasis in control and Adipo-AKT KO mice. 
Adipo-AKT KO mice had glucose tolerance comparable to control mice at 8-12 weeks of 
age (Figure 2-4A). However, while control mice had fasting insulin levels of ~0.5 ng/mL, 
levels in the KO mice were appreciably higher at 2.5 ng/mL, indicative of significant 
insulin resistance (Figure 2-4B). To further investigate the ability of Adipo-AKT mice to 
regulate blood glucose in the face of insulin resistance, we fasted mice overnight and 
challenged them with a meal of normal chow. Two hours after refeeding, blood glucose 
levels were significantly greater in the Adipo-AKT mice than the controls (Figure 2-4C). 
Consistent with the results from GTT, the insulin levels were elevated in fasted Adipo-
AKT KO and increased even further following feeding (Figure 2-4D). 
Plasma non-esterified fatty acids (NEFA) levels were also measured during 
fasting and after a 2 hour feeding challenge on normal chow. Adipo-AKT KO mice had 
low basal NEFA levels of 0.7 mmol/L compared to control mice that had fasting NEFA of 
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1.6 mmol/L. Postprandially, NEFA levels in control mice are suppressed to 0.68 mmol/L 
while in Adipo-AKT KO mice NEFA levels were not changed (Figure 2-4E). 
 
Discussion 
Our findings indicate that AKT1 and/or AKT2 are required for adipose 
maintenance in vivo. The severity of insulin resistance in the Adipo-AKT KO mice and 
their inability to regulate blood glucose postprandially follows the pattern observed in 
human patients with lipodystrophy, many of whom develop frank diabetes following 
puberty (Agarwal et al., 2002; Garg, 2004; 2000). Multiple mouse models of 
lipodystrophy have been developed that recapitulate characteristics of human 
lipodystrophy. Mutations in AGPAT-2 and BSCL-2/seipin account for most human 
lipodystrophy patients, CGL Type I and CGL Type II, respectively (Agarwal et al., 2002; 
Magré et al., 2001), and mice null for these genes have lipodystrophic and insulin 
resistant phenotypes (CortEs et al., 2009; Cui et al., 2011). Several other genes have 
been manipulated in mice resulting in lipodystrophy, notably the AZIP/F-1 dominant 
negative mouse, which interferes with adipocyte development, the lamin A (LMNA) 
dominant negative mouse that inhibits adipose renewal, and adipocyte-specific loss of 
peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor 
required for adipocyte differentiation and maintenance (Moitra et al., 1998; Shimomura 
et al., 1998; F. Wang et al., 2013; Wojtanik et al., 2009).   
Studies performed in vitro established that AKT signaling is necessary for 
adipogenesis in cultured cells (Bae et al., 2003; Baudry, 2006; Nakae et al., 2003; Peng 
et al., 2003; Yun et al., 2008). AKT1 is required for adipogenesis in mouse embryo 
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fibroblasts (MEFs) and 3T3L1 preadipocytes, while AKT2 is dispensable (Bae et al., 
2003; Baudry, 2006; Yun et al., 2008).  Mechanistically, AKT functions in precursor cells 
to suppress Foxo1 activity (Nakae et al., 2003; Yun et al., 2008).  The isoform specificity 
in vitro are in conflict with in vivo data from Akt1 null mice, that have an overall smaller 
body size but do not exhibit a lipodystrophic phenotype (W. S. Chen et al., 2001; Cho et 
al., 2001).  This suggests that either non-autonomous factors influence adipogenesis, or 
that AKT2 can support adipogenesis in the whole animal. Additionally, Akt2 null mice 
have been suggested to develop an age-dependent lipodystrophy (Garofalo et al., 
2003). Our data expand on these studies and document a critical role for AKT signaling 
in maintaining mature adipocytes  
The AdipoQ-Cre transgene is thought to be mainly expressed in mature 
adipocytes (Berry and Rodeheffer, 2013; Eguchi et al., 2011; K. Y. Lee et al., 2013; 
Mullican et al., 2013). Mullican, et al (2013) and Lee, et al (2013), showed that 
recombination does not occur in the stromal vascular fraction of adipose tissue depots 
(K. Y. Lee et al., 2013; Mullican et al., 2013). Consistent with this, Berry and Rodeheffer 
(2013) found that highly purified adipogenic precursor cells in WAT do not express 
AdipoQ-Cre (Berry and Rodeheffer, 2013). Interestingly, a recent study shows that 
adiponectin is expressed at the embryonic stage in adipocyte precursors of inguinal 
WAT, but not in adult preadipocytes (Hong et al., 2015). It is unclear if AdipoQ-Cre is 
also expressed at sufficient levels in this population to induce efficient recombination.  
Moreover, it is not known if adipose precursors of other depots, such as the epididymal 
WAT similarly express adiponectin during embryogenesis.  The AdipoQ-Cre mediated 
deletion of AKT in our model may thus reflect defects in adipocyte differentiation and 
maintenance, depending on the depot.   
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There are three AKT isoforms, AKT1-3, that function in the insulin signaling 
pathway. Each of these isoforms is expressed in adipocytes, but AKT2 is the most 
abundant isoform (Altomare et al., 1998; Walker et al., 1998). Mice null for Akt1 and Akt2 
are born with dwarfism, are not viable, and MEFs derived from these animals are unable 
to undergo adipogenesis (Peng et al., 2003). AKT3 is expressed in differentiated 
adipocytes (Easton et al., 2005), but it is clearly not sufficient to preserve adipocyte 
insulin/IGF signaling in the absence of both AKT1 and AKT2.. 
The insulin and insulin-like growth factor 1 (IGF-1) pathways converge on the 
insulin receptor substrate and phosphoinositide-3-kinase (PI3K), upstream of AKT 
(Nakae et al., 2000; Stokoe et al., 1997; Withers et al., 1999). Loss of AKT1 and AKT2 in 
adipocytes likely ablates both insulin signaling and IGF-1 signaling, potentially 
contributing to the severity of the lipodystrophy. Concurrent deletion of the insulin 
receptor and insulin growth factor 1 receptor (IGF1R) using aP2-Cre causes 
lipodystrophy with IGF1R signaling having a more important role in BAT than in WAT 
(Boucher et al., 2012). While the requirement for IR and IGF1R signaling may differ 
between depots, all depots depend on AKT-function.  
The Adipo-AKT KO mice display profound hepatomegaly and a small but 
significant renomegaly along with increased pancreas weight (Figures 2-2C and 2-3D).  
This organomegaly is also observed in some human lipodystrophic patients, with 
hepatomegaly often being most prominent (Garg, 2004; LAWRENCE, 1946; Misra and 
Garg, 2003; ZIEGLER, 1928). Hyperinsulinemia potentially contributes to the increased 
body size and organomegaly of Adipo-AKT mice through enhanced IR/IGF-1 signaling. 
Another possible contributor to organomegaly is increased food intake as a result of 
reduced circulating levels of leptin (Figure 1E), a critical regulator of energy 
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homeostasis. (Asilmaz et al., 2004; W. S. Chen et al., 2009; CortEs et al., 2014; Ebihara 
et al., 2001; Shimomura et al., 1999).  
Surprisingly, Adipo-AKT KO mice had low plasma NEFA levels, a phenomenon 
also observed in some human lipodystrophic patients (Savage et al., 2003). These 
patients exhibit post-prandial plasma NEFA levels unchanged from their fasting levels 
(Savage et al., 2003). Similarly, the Adipo-AKT KO mice had refed NEFA levels that 
were not significantly differently from either their fasted levels or the fed levels in control 
mice. In many mouse models of lipodystrophy, there are high fed plasma NEFA levels 
(Moitra et al., 1998; Shimomura et al., 1998; F. Wang et al., 2013). Interestingly, genetic 
background influences lipid profiles in lipodystrophic AZIP/F-1 mice (Colombo et al., 
2003). On a FVB background AZIP/F-1 mice have abnormally high NEFA levels, 
whereas NEFA levels are similar between control and AZIP/F-1 mice on a C57/B6 
background (Colombo et al., 2003). Similarly, Agpat2 and Bscl-2/seipin null mice, both in 
the C57/B6 background, have normal NEFA levels (CortEs et al., 2009; Cui et al., 2011). 
These mice, and the C57/B6 AZIP/F-1 mice, have significantly decreased fasting NEFA 
levels (Moitra et al., 1998), similar to the Adipo-AKT KO mice.  By contrast, adipocyte-
specific deletion of Bscl-2/seipin results in a milder lipodystrophy and these mice do not 
have reduced fasting NEFA levels (L. Liu et al., 2014). Given the severity of 
lipodystrophy in the Adipo-AKT KO mice, it follows that they have no available adipose 
stores to undergo lipolysis and release fatty acids in response to a fasting state.  
Conclusions 
Our mouse model recapitulates many of the features observed in a familial 
lipodystrophy syndrome caused by loss of function mutations in Akt1 and Akt2, including 
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insulin resistance and hepatomegaly (George, 2004). Our study also demonstrates that 
AKT signaling, likely acting downstream of the insulin and IGF-1 receptor, are critically 
required for proper adipose expansion and/or maintenance.  
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Figure 2-1. Adipo-AKT knockout mice are lipodystrophic. A. Control and Adipo-AKT 
KO mice lack subscapular white and brown fat depots (black box). B. Epididymal fat 
pads and fat pad weights from control and Adipo-AKT KO mice (control n=4, Adipo-AKT 
KO n=6). C. H&E staining of the epididymal fat pad depots. D. F4/80 staining of the 
epididymal fat pad depots. E. Circulating canonical adpiokines leptin, adiponectin, and 
resistin (control n=9, Adipo-AKT KO n=8). F. Growth curve of control and Adipo-AKT KO 
mice (control n=10, Adipo-AKT KO n=12). All data are presented as mean +/- s.e.m. (*, 
p<.05; ****, p<.0001).  
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Figure 2-2. Adipo-AKT knockout mice have hepatomegaly. A. Adipo-AKT KO mice 
have enlarged and pale livers. B. Liver weights in control and Adipo-AKT mice. (control 
n=4, Adipo-AKT KO n=6). C. Stored liver triglycerides in liver of control and Adipo-AKT 
mice (n=6).  D. H&E staining of the liver from control and Adipo-AKT KO mice (20x).  All 
data are presented as mean +/- s.e.m. (*, p<.05; ****, p<.0001).  
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Figure 2-3. Adipo-AKT KO mice have enlarged pancreases and renomegaly. A. 
Organ weights of control and Adipo-AKT mice (control n=4, Adipo-AKT KO n=6).  B. 
H&E staining of the spleen (10x). C. H&E staining of the kidney (10x). D. H&E staining of 
the pancreas (10x). All data are presented as mean +/- s.e.m. (*, p<.05). 
 
 
 
Figure 2-3. 
 
Pa
nc
rea
s
He
art
Sp
lee
n
Ki
dn
ey
0.0
0.5
1.0
1.5
2.0
O
rg
an
 w
ei
gh
ts
 (%
 b
od
y 
w
ei
gh
t)
Control
Adipo-AKT KO
A.
*
Organ weights 
(% body weight)
Control Adipo-AKT KO
*
Control Adipo-AKT KO Control Adipo-AKT KO
B. C.
D.
Pa
nc
rea
s
He
art
Sp
lee
n
Ki
dn
ey
0.0
0.1
0.2
0.3
0.4
O
rg
an
 w
ei
gh
ts
 (g
)
*
*
Organ weights (g)
55	  
	  
Figure 2-4. Adipo-AKT mice are insulin-resistant. A. Glucose tolerance tests were 
performed after an overnight fast, time 0, and 1g/kg glucose was injected 
intraperitoneally with glucose measurements taken at 0, 15, 30, 60, and 120 minutes 
(control n=9, Adipo-AKT KO n=19). B. Serum insulin levels were collected at time 0 and 
15 minutes after glucose injection. (control n=8, Adipo-AKT KO n=14). C. Blood glucose 
levels following an overnight fast and 2 hour meal challenge in control and Adipo-AKT 
KO mice (control n=8, Adipo-AKT KO n=11). D. Serum insulin levels following an 
overnight fast and 2 hour meal challenge in control and Adipo-AKT KO mice (control 
n=5, Adipo-AKT KO n=11). E. Serum non-esterified fatty acids after an overnight fast 
and 2 hour meal challenge (control n=4, Adipo-AKT KO n=6).  All data are presented as 
mean +/- s.e.m. (*, p<.05; ****, p<.0001). 
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CHAPTER 3: 
 
Adipocyte AKT2 controls circulating free fatty acids and 
systemic insulin sensitivity 
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Introduction 
The tightly controlled physiological processes within insulin-responsive tissues 
are disrupted in insulin resistance (IR) and Type 2 Diabetes (T2D). Adipose tissue is a 
critical regulator of energy homeostasis and adipocyte metabolism is perturbed during 
insulin resistance. Conversely, defective insulin signaling in adipocytes can precipitate 
systemic insulin resistance (Abel et al., 2001; Qiang et al., 2016; Shan et al., 2016; 
Softic et al., 2016; Tang et al., 2016; Vazirani et al., 2016). Several studies have shown 
that a decrease in adipocyte glucose uptake blunts de novo lipogenesis (DNL), resulting 
in hepatic insulin resistance (Abel et al., 2001; Herman et al., 2013; Tang et al., 2016; 
Vazirani et al., 2016).  Decreased adipose DNL also correlates with insulin resistance in 
humans(Roberts et al., 2009). Conversely, experimentally induced increases in glucose 
uptake and elevated DNL protects mice against diet induced insulin resistance (Girousse 
et al., 2013; Herman et al., 2013; Moraes-Vieira et al., 2016; Yore et al., 2014). The 
insulin-responsive glucose transporter Glut4 is largely intracellular until the insulin 
receptor is engaged. Upon activation of insulin signaling, the serine/threonine kinase 
AKT inactivates the Rab GTPase that maintains Glut4 at the lysosome, allowing Glut4 to 
translocate to the cell membrane (Bae et al., 2003; Blot and McGraw, 2008; Mueckler, 
2001; Watson and Pessin, 2006). 
AKT is a central regulator of insulin signaling, though its in vivo role in adipose 
tissue remains poorly defined. AKT1 accounts for a small percentage of total AKT in the 
adipocyte and Akt1 null mice, while smaller in overall body size than wild type mice, 
have normal adiposity (Altomare et al., 1998; Cho et al., 2001; Walker et al., 1998). 
Adipocyte-selective ablation of both AKT1 and AKT2 causes severe lipodystrophy, 
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suggesting that AKT1 and AKT2 have redundant functions in adipocyte differentiation 
and maintenance (Shearin et al., 2016).  
In contrast to Akt1 null mice, Akt2 null mice are insulin resistant; exhibiting 
defects in insulin-stimulated glucose uptake in to muscle and adipose, as well as 
incomplete suppression of hepatic glucose production (Cho, 2001; Garofalo et al., 2003). 
However, it was unclear if the deficit in adipose glucose uptake is adipocyte-autonomous 
or secondary to the systemic insulin resistance observed in this model.  In this study, we 
used the AdipoQ-Cre to delete Akt1 (Adipo-AKT1 KO) or Akt2 (Adipo-AKT2 KO) 
selectively in adipocytes. The loss of Akt1 did not impact insulin sensitivity, with no 
notable changes in glucose tolerance, fasting insulin levels, insulin levels following a 
meal challenge, or response to insulin stimulation. By contrast, Adipo-AKT2 KO mice 
displayed profound adipose and systemic insulin resistance, with fasting 
hyperinsulinemia and an inability to suppress hepatic glucose production during a 
hyperinsulinemic-euglycemic clamp. We show that AKT2 KO mice display defects in 
insulin-stimulated glucose-uptake into adipocytes and in suppression of adipose lipolysis 
resulting in elevated levels of circulating FFAs.  Loss of glucose uptake alone in 
adipocytes was not sufficient to cause hepatic insulin resistance. We conclude that 
increased FFA levels lead to systemic insulin resistance by stimulating persistent hepatic 
gluconeogenesis in the face of hyperinsulinemia. 
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Results 
Lack of adipocyte AKT2, but not AKT1, causes hyperinsulinemia and insulin resistance  
We previously reported that concurrent deletion of AKT1 and AKT2 in mice 
causes severe lipodystrophy (Shearin et al., 2016). However, loss of either Akt1 or Akt2 
alone does not cause a profound loss of fat tissue (Figure 3-1A, B). We used a variety of 
approaches to assess glucose homeostasis and insulin sensitivity in Adipo-AKT1 KO 
and Adipo-AKT2 KO mice. Adipo-AKT1 KO mice have normal glucose homeostasis and 
normal insulin levels during fasting in response to either a glucose or meal challenge 
(Figure 3-1C, D, E, F). These mice also respond to an insulin stimulation of 0.75 U/kg in 
a manner similar to control mice (Figure 3-1H). In contrast, mice lacking adipocyte AKT2 
retain glucose homeostasis, but are hyperinsulinemic following an overnight fast (Control 
insulin = 0.5 ng/mL, Adipo-AKT2 KO insulin = 1.1 ng/mL) and 15 minutes after receiving 
a glucose bolus (Control insulin = 0.5 ng/mL, Adipo-AKT2 KO insulin = 1.8 ng/mL) 
(Figure 3-1C, D). During a 2 hour meal challenge, Adipo-AKT2 KO mice had an elevated 
insulin level of 8.2 ng/mL, compared to the control insulin level of 2.2 ng/mL (Figure 3-
1F). Additionally, Adipo-AKT2 KO mice were unable to fully suppress serum free fatty 
acids (FFAs) in response to a meal (Figure 3-1G) or insulin-bolus (Figure 1H). Adipo-
AKT2 KO mice had blunted glucose lowering response to insulin stimulation (Figure 3-
1H). Insulin levels following a 5 hr fast trended towards being elevated in the Adipo-
AKT2 KO mice, and were equally elevated as controls at the 30 minute time point 
(Figure 3-1I).  
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Adipo-AKT2 mice have functional adipose insulin resistance 
The loss of AKT2 did not cause a compensatory increase in AKT1 levels in 
gonadal WAT from Adipo AKT2 KO mice and panAKT levels were reduced by > 50%.  
This is consistent with whole WAT depots consisting of ~50% adipocytes. AKT2 deletion 
in adipocytes significantly reduced AKT-phosphorylation in WAT in response to a 2 hour 
meal challenge.  However, downstream targets Foxo and PRAS40 are phosphorylated 
at similar levels in Control and AKT2 KO WAT (Figure 3-2A). Proteins involved in 
regulating lipolysis are highly active and phosphorylated during the fasting state and are 
dephosphorylated in the fed state. Hormone-sensitive lipase (HSL) is dephosphorylated 
normally in AKT2 KO WAT compared to controls (Figure 3-2A). Histochemical analysis 
showed that adipocytes in KO WAT have a more uniform sizes compared to the 
heterogeneous distribution of adipocyte size in WAT from  control mice (Figure 3-2B). 
On NMR analysis, these mice exhibit a mild but significant decrease in overall adiposity 
(Figure 3-2C), consistent with blunted insulin-stimulated glucose uptake in isolated 
epididymal adipocytes from Adipo-AKT2 KO mice (Figure 3-2D).  
 
Circulating adiponectin is reduced in Adipo-AKT2 KO mice 
 To ask if adipocyte function was normal other than glucose uptake, we measured 
the circulating adipokine levels in Adipo-AKT2 KO mice. Adiponectin levels were 
significantly decreased by ~40% (Control = 12.8 ug/mL, Adipo-AKT2 KO = 7.9 ug.mL), 
while leptin and resisin levels are normal (Control = 0.56 ng/mL, Adipo-AKT2 KO = 0.41 
ng/mL; Control = 1.8 ng/mL, Adipo-AKT2 KO = 1.6 ng/mL, respectively) (Figure 3-3A, B, 
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C). AKT2-dependent insulin signaling may specifically affect adiponectin translation or 
secretion in adipose tissue.  
 
Adipo-AKT2 KO mice have mild hepatomegaly and enlarged islets 
 Histopathology of livers and pancreases from Adipo-AKT2 KO mice reveal what 
may be increased accumulated triglyceride in hepatocytes (Figure 3-4A), and enlarged 
islets (Figure 3-4B). Liver weights were slightly increased as a percentage of body 
weight (Control = 5%, Adipo-AKT2 KO = 6%) (Figure 3-4C). Pancreas size was not 
increased (Control = 1.03%, Adipo-AKT2 KO = 1.06%) (Figure 3-4C). The concentration 
of liver triglyceride trends towards increased in Adipo-AKT2 KO mice, but does not reach 
significance because of variability within the KO livers (Control = 6.3 mgTg/gLiver, 
Adipo-AKT2 KO = 9.1 mgTg/gLiver) (Figure 3-4D).   
 
Serum chemistries in the ad libitum state in control and Adipo-AKT2 KO mice reveal 
hyperinsulinemia and a trend towards increased FFAs. 
 Serum chemistries in control and Adipo-AKT2 KO state taken at 10 am in non-
fasted animals reveal significant hyperinsulinemia and a trend towards increased free 
fatty acid levels, but glycerol and serum ketone levels are normal (Table 3-1.) 
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Adipo-AKT2 KO mice aged 9-12 months do not exhibit glucose intolerance 
 To challenge the Adipo-AKT2 KO mice, we aged a cohort to 9-12 months of age 
and measured their glucose homeostasis and plasma insulin levels. At this time point, 
the Adipo-AKT2 KO mouse retains glucose tolerance and normal glucose homeostasis 
during a 2 hour meal challenge (Figure 3-5A, C). Fasting hyperinsulinemia and 
increased insulin levels following a glucose bolus and 2 hour meal challenge are still 
present, with refed insulin levels higher than those present in 8-12 week old Adipo-AKT2 
KO mice (Control = 3.2 ng/mL, Adipo-AKT2 KO = 15.3 ng/mL) (Figure 3-5B, D). FFAs 
were also still defective in their suppression following a refeed (Control = 0.3 mmol/L, 
Adipo-AKT2 KO = 0.7 mmol/L) (Figure 3-5E). By 9-12 months of age, liver triglyceride 
levels have increased in the Adipo-AKT2 KO mouse, with significantly elevated 
concentration of triglyceride observed (Control = 6 mgTg/gLiver, Adipo-AKT2 KO = 37.4 
mgTg/gLiver) (Figure 3-5F).  
 
Loss of AKT2 in adipocytes causes hepatic and muscle insulin resistance 
To further assess insulin action in Adipo-AKT2 KO mice, we performed a 
hyperinsulinemic-euglycemic clamp, using 2.5mU/kg/min insulin following a 5 hour fast. 
AKT2 KO mice exhibited severe systemic insulin resistance. Control mice had an 
average glucose infusion rate during the clamped period of 55 mg/kg/min, while Adipo-
AKT2 KO mice averaged 8.2 mg/kg/min (Figure 3-6B). Adipo-AKT2 KO mice displayed 
about a 50% decrease in glucose uptake in response to insulin (Control = 62 mg/kg/min, 
Adipo-AKT2 KO = 32 mg/kg/min) (Figure 3-6C). Glucose uptake into both brown adipose 
tissue (Control = 2078 nmol/g/min, Adipo-AKT2 KO = 156.5 nmol/g/min) and skeletal 
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muscle (Control = 223.5 nmol/g/min, Adipo-AKT2 KO = 75.5 nmol/g/min) was blunted in 
KO relative to Control mice (Figure 3-6G, H). The KO mice were also unable to suppress 
hepatic glucose production (HGP) at this dose of insulin (Figure 3-6D). During the clamp, 
control mice had an HGP of 7.2 mg/kg/min compared to 24 mg/kg/min in KO animals, 
which was not significantly different than their HGP prior to the start of the clamp (Figure 
3-6D). FFAs were suppressed by 60% in clamped control mice and by only 30% in 
Adipo-AKT2 KO mice (Figure 3-6E). This difference in percent suppression of FFAs 
between Control and KO mice was highly significant  (Figure 3-6F). Given the decrease 
in hepatic insulin sensitivity, we asked if insulin signaling in the liver was intact following 
the clamp study. Phosphorylation of Akt in the liver of Adipo-AKT2 KO mice was 
equivalent to p-AKT levels in control livers (Figure 3-6I). To further establish hepatic 
insulin action in Adipo-AKT2 KO mice, we measured the transcription levels of genes 
suppressed in response to insulin in the livers of both control and Adipo-AKT2 KO mice 
following the clamp. Transcription levels of these genes were equivalent (Figure 3-6J).  
Together, these results indicate that Adipo-AKT KO mice display profound hepatic and 
systemic insulin resistance. 
 
Mice with adipocyte-specific loss of Glut4 do not have hyperinsulinemia or glucose 
intolerance 
Several studies have suggested that a defect in adipose glucose uptake in 
response to insulin can result in hepatic insulin resistance ((Abel et al., 2001; Tang et al., 
2016; Vazirani et al., 2016)). To ask if this accounted for the insulin resistance in Adipo-
AKT2 KO, we generated mice lacking Glut4 in adipocytes using the AdipoQ-Cre driver 
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(Adipo-Glut4 KO). As anticipated, Glut4 mRNA levels were substantially reduced in 
gonadal WAT of Adipo-Glut4 KO animals (Figure 3-7A). The gonadal fat pads from 
Adipo-Glut4 KO mice appeared grossly normal and were similar to those from control 
mice (Figure 3-7B). Control and Adipo-Glut4 KO mice of both sexes responded normally 
to an intraperitoneal injection of 1g/kg glucose and did not display hyperinsulinemia 
following an overnight fast or in response to the glucose bolus (Figure 3-7C, D). Adipo-
Glut4 KO mice also had normal glucose homeostasis and insulin levels in response to a 
2 hour meal challenge following an overnight fast (Figure 3-7E, F). Both male and 
female Adipo-Glut4 KO mice responded normally to an insulin stimulation of 0.75U/kg 
following a 5 hour fast and insulin levels were consistent both following the fast and the 
insulin bolus (Figure 3-7G, H).  
 
Female mice with adipocyte-specific deletion of Glut4 do not have hepatic insulin 
resistance  
We performed hyperinsulinemic-euglycemic clamp studies on female Adipo-
Glut4 KO and control mice using a dose of 2.5 mU/kg/min insulin following a 5 hour fast. 
The KO mice displayed a significant decrease in both glucose infusion rate (Control = 
76.4 mg/kg/min, Adipo-Glut4 KO = 45.9 mg/kg/min) (Figure 3-8A) and whole-body 
glucose disposal (Control = 69.4 mg/kg/min, Adipo-FeGlut4 KO = 47.2 mg/kg/min) 
(Figure 3-8B).  HGP was suppressed by insulin to a similar extent in the KO and control 
animals with HGP in clamped controls and KOs of -6 mg/kg/min and 1.28 mg/kg/min, 
respectively (Figure 3-8C). Glucose uptake into brown adipose tissue was significantly 
decreased in KO relative to control animals (Control = 1340 nmol/g/min, Adipo-FeGlut4 
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KO = 126.2 nmol/g/min) (Figure 3-8D). Glucose uptake into skeletal muscle was not 
significantly different between Control and KO mice (Control = 302.5 nmol/g/min, Adipo-
FeGlut4 KO = 229.8 nmol/g/min), but trended towards being decreased in the KO 
animals (Figure 3-8E).  
 
Male Adipo-Glut4 KO mice do not have insulin resistance 
 In addition to clamping female mice without adipocyte Glut4 for comparison to 
published insuin sensitivity data for aP2-Cre Glut4 KO mice and AdipoQ-Cre Rab10 KO 
mice, we clamped male Adipo-Glut4 KO mice to compare to the Adipo-AKT2 KO mice. 
These mice have normal insulin sensitivity on a hyperinsulinemic-euglycemic clamp 
study compared to littermate control mice. Glucose infusion rates were Control = 25.7 
mg/kg/min, Adipo-MGlut4 KO = 31.2 mg/kg/min (Figure 3-9A). Whole-body glucose 
disposal was Control = 36.5 mg/kg/min, Adipo-MGlut4 KO = 39 mg/kg/min (Figure 3-9B). 
Hepatic glucose production was not significantly suppressed in control or Adipo-MGlut4 
KO mice at a 2.5 mU/kg/min dose of insulin during the clamp, with HGP during insulin 
delivery at Control = 10.75 mg/kg/min and Adipo-MGlut4 KO = 7.8 mg/kg/min (Figure 3-
9C).  
 
Transcription of ChREBP and FASN are reduced in Adipo-AKT2 KO mice 
 Mice without adipocyte AKT2 have changes in the transcription of total ChREBP 
(Control = 1 A.U., Adipo-AKT2 KO = 0.3 A.U.) (Figure 3-10A). However, this does not 
result in a loss of the DNL transcription program in the adipocyte, but rather only in a 
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loss of expression of the rate-limiting step in DNL, FAS (Figure 3-10B). ChREBPβ 
isoform trends towards a decrease, but does not reach significance, as does ATP citrate 
lyase (Figure 3-10B). No other major transcriptional changes are observed for the genes 
queried in the Adipo-AKT2 KO adipose tissue, with normal levels of cd36, the fatty acid 
transporter, ATGL, and CGI-58, even when the mice were challenged with refeeding 
(Figure 3-10C, D, E). Adipose tissue from male Adipo-Glut4 KO mice did not reveal any 
changes in the DNL program, at the ChREBP level or at any downstream targets (Figure 
3-10F).  
 
Other published mechanisms of adipocyte insulin resistance are unchanged in Adipo-
AKT2 KO mice 
 aP2-Cre Glut4 KO mice have revealed several potential mechanisms for the 
propagation of insulin resistance. We asked if any of these established mechansims 
contribute to the insulin resistance in the Adipo-AKT2 KO mice. We found that retinol 
binding protein 4 expression levels were similar in control and Adipo-AKT2 KO mice 
(Figure 3-11A). Additionally, no changes were observed in adipose tissue expression of 
genes involved in regulation of redox (Figure 3-11B). The same is true for fatty acid 
binding protein 4 expression levels (Figure 3-11C) and tumor necrosis factor alpha 
expression levels (Figure 3-11D). We also observed no compensatory increase in Glut1 
expression to compensate for the reduction in glucose uptake documented in the Adipo-
AKT2 KO adipocyte (Figure 3-11E).  
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Discussion 
Deletion of Akt2 and associated insulin resistance in adipocytes causes profound 
systemic insulin resistance, but not glucose intolerance (Figure 3-1C, H). Despite 
elevated insulin levels during the clamp study, Adipo-AKT2 KO mice are unable to 
suppress hepatic glucose production and have blunting of adipose and muscle glucose 
uptake (Figure 3-6D, G, H)  
We postulated that reduced insulin-stimulated glucose uptake into adipose was 
responsible for the systemic insulin resistance in the Adipo-AKT2 KO model (Figure 3-
2D, 3G). To test this idea, we generated mice with AdipoQ-Cre driven deletion of the 
glucose transporter 4 (Glut4), which mediates insulin-dependent glucose transport 
(Adipo-Glut4 KO). By contrast, these mice exhibit insulin levels and sensitivity similar to 
control mice under our experimental conditions (Figure 3-7). On a clamp study, we found 
the Adipo-Glut4KO mice have a reduced glucose infusion rate and reduced glucose 
disposal, but they do not show a significant defect in muscle glucose uptake and 
suppress hepatic glucose production to levels similar to control mice (Figure 3-8A-E). 
These results differ from previously reported results by Abel, et al (2001) (Abel et al., 
2001). Potential confounding variables may be the use of the aP2-Cre, which is now 
known to be expressed in muscle, liver, and brain, all organs critical in the regulation of 
insulin sensitivity (K. Y. Lee et al., 2013; Mullican et al., 2013). Other important factors 
may include the environment of the mouse facility or the age at which the mice were 
studied.  
Loss of insulin-stimulated glucose uptake has been shown to suppress DNL 
(Herman et al., 2013; Moraes-Vieira et al., 2016; Tang et al., 2016; Yore et al., 2014). 
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We noted that Adipo-AKT2 KO mice have decreased total carbohydrate response 
element binding protein (ChREBP) expression levels and a trending decrease in the 
isoform ChREBP-β expression (Figure 3-9A, B). Consistent with this, fatty acid synthase 
(FAS) expression, the committed step for DNL, was also decreased. However, other 
genes in the DNL cascade were unchanged in AKT KO mice including acetyl-coA 
carboxylase, and ATP-citrate lyase.  These results suggest that while decreases in DNL 
and adipocyte glucose uptake may contribute to the systemic insulin resistance, there 
are likely to be additional mechanisms involved (Figure 3-9B).  
A distinctive and striking feature of the Adipo-AKT2 KO metabolic phenotype is 
the reduced suppression of FFA levels following a meal or insulin bolus (Figure 1G, J). 
These data suggest that AKT2 is required in adipocytes to fully suppress lipolysis and 
this is supported by the defect in dephosphorylation of perilipin in response to a meal 
(Figure 2A).  
Several studies have proposed that adipocyte metabolism can regulate hepatic 
insulin sensitivity in a cell non-autonomous manner (Perry et al., 2015; Titchenell et al., 
2016). Our data support this model, in that Adipo-AKT2 KO mice display profound 
hepatic insulin resistance in the absence of an overt defect in insulin signaling, as 
measured by p-AKT levels (Figure 3-6I, J). 
In summary, our studies highlight a central role for adipocyte insulin signaling in 
controlling systemic insulin action.  (Moore et al., 2004; Perry et al., 2015; Titchenell et 
al., 2016). Here we show that disruption of insulin signaling in the adipocyte at the 
central Ser/Thr kinase AKT2 is sufficient to cause functional adipocyte insulin resistance, 
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leading to defects in glucose uptake and suppression of lipolysis. This loss of adipocyte 
insulin sensitivity is sufficient to instigate downstream systemic insulin resistance.  
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Figure 3-1. Lack of adipocyte AKT2, but not AKT1, causes hyperinsulinemia and 
insulin resistance. A. Deletion of AKT1 and AKT2 individually in an adipose tissue. B. 
Adipose tissue without either Akt1 or Akt2 maintains normal gross appearance. C. Mice 
lacking adipose AKT1 or AKT2 retain glucose tolerance (AKT1-Control n=9, Adipo-AKT1 
KO n=7, AKT2-Control n=8, Adipo AKT2 KO n=10). D. Plasma insulin levels after 
overnight fasting and following a glucose bolus (AKT1-Control n=7, Adipo-AKT1 KO n=6, 
AKT2-Control n=8, Adipo AKT2 KO n=8) E. Glucose homeostasis during a 2 hour meal 
challenge (AKT1-Control n=7, Adipo-AKT1 KO n=6, AKT2-Control n=5, Adipo AKT2 KO 
n=6). F. Fasting plasma insulin levels and following a 2 hour meal challenge (AKT1-
Control n=7, Adipo-AKT1 KO n=6, AKT2-Control n=10, Adipo AKT2 KO n=14). G. 
Fasting plasma FFAs levels and after a 2 hour meal challenge in control and Adipo-
AKT2 KO mice (AKT2-Control n=17, Adipo AKT2 KO n=8). Insulin tolerance test with 
0.75 U/kg insulin after a 5 hr fast. (AKT1-Control n=6, Adipo-AKT1 KO n=6, AKT2-
Control n=8, Adipo AKT2 KO n=7). I. Insulin levels before and after insulin stimulation 
(AKT1-Control n=6, Adipo-AKT1 KO n=6, AKT2-Control n=8, Adipo AKT2 KO n=7). J. 
Plasma FFAs before and after ITT for control Adipo-AKT2 KO mice (AKT2-Control n=8, 
Adipo AKT2 KO n=7). 
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Figure 3-1. 
73	  
	  
Figure 3-2.  Adipo-AKT2 mice have functional adipose insulin resistance. 
A. Immunoblots from epididymal fat pads of control and Adipo-AKT2 KO mice. AKT1 is 
not upregulated in a compensatory manner and pan-AKT is down. Phosphorylation of 
AKT is decreased, but signaling to FOXO and PRAS40 is retained, as well as 
dephosphorylation of HSL. Dephosphorylation of Perilipin is blunted. B. H&E staining of 
epididymal fat pads from control and Adipo-AKT2 mice. C. Adipo-AKT2 mice have a 
significant decrease in their overall fat mass (Control n=5, KO n=5). D. Adipocytes 
pooled and isolated from control and Adipo-AKT2 KO epididymal fat pads were 
stimulated with insulin and have a significant difference in uptake of radiolabeled 
glucose. Graph is representative of two experiments. (Control n=3, Adipo-AKT2 KO n=3, 
per experiment).  
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Figure 3-2. 
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Figure 3-3. Circulating adiponectin is reduced in Adipo-AKT2 KO mice. A, B, C. 
Adiponectin, Leptin, and Resistin levels in control and Adipo-AKT2 KO mice. (Control 
n=11, KO n=12). 
 
 
Figure 3-3. 
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Figure 3-4. Adipo-AKT2 KO mice have mild hepatomegaly and enlarged islets. A 
and B. Histopathology on the liver and pancreas of control and Adipo-AKT2 KO mice 
(20x). C. Weights as % body weight for the liver and pancreas of control and Adipo-
AKT2 KO mice (Control n=9, KO n=9). D. Liver triglyceride concentration in control and 
Adipo-AKT2 KO mice (Control n=8, KO n=10).  
 
 
 
 
Figure 3-4. 
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Table 3-1. Serum chemistries in the ad libitum state for control and Adipo-AKT2 
KO mice. (Control n=5, Adipo-AKT2 KO n=5). 
 
 Insulin FFAs Glycerol Ketones 
Control 0.89 0.63 0.37 0.15 
Adipo-AKT2 
KO 
3.70 0.79 0.38 0.14 
p-value 0.0006 0.1940 0.8251 0.6629 
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Figure 3-5. Adipo-AKT2 KO mice aged 9-12 months do not exhibit glucose 
intolerance. A. Glucose tolerance tests at 1g/kg injected intraperitoneally after an 
overnight fast. B. Insulin after an overnight fast and 15 minutes following the glucose 
injection. C. Glucose levels after an overnight fast and 2 hours after a meal challenge. D. 
Insulin levels after an overnight fast and 2 hours after a meal challenge. E. FFAs levels 
after an overnight fast and 2 hours after a meal challenge. F. Liver triglyceride 
concentration in control and KO mice. (Control n=4, KO n=5).  
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Figure 3-5. 
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Figure 3-6. Loss of adipocyte AKT2 causes hepatic and muscle insulin resistance. 
Mice were fasted for 5 hours and then clamped at 2.5 mU/kg/min insulin. A. Insulin 
levels before and after the hyperinsulinemic clamp (Control n=3, Adipo-AKT2 KO n=3). 
B. Glucose infusion rate for control and Adipo-AKT2 KO mice during the clamp (Control 
n=5, Adipo-AKT2 KO n=5). C. Whole body glucose disposal for control and Adipo-AKT2 
KO mice (Control n=5, Adipo-AKT2 n=5). D. Basal and clamped hepatic glucose 
production in control and Adipo-AKT2 KO mice (Control n=5, Adipo-AKT2 KO n=5). E. 
Plasma FFAs levels during the clamp in both control and Adipo-AKT2 KO mice, (Control 
n=5, Adipo-AKT2 KO n=5). F. Percent suppression of FFAs during the clamp in control 
and Adipo-AKT2 KO mice (Control n=5, Adipo-AKT2 KO n=5). G. Insulin responsive 
glucose uptake in to brown adipose tissue during the clamp in control and Adipo-AKT2 
KO mice (Control n=2, Adipo-AKT2  KO n=2). H. Glucose uptake in skeletal muscle 
during the clamp in control and Adipo-AKT2 KO mice (Control n=2, Adipo-AKT2 n=2). I. 
Phosphorylation of AKT in Adipo-AKT2 KO liver samples compared to control following 
hyperinsulinemic-euglycemic clamp (Control n=3, Adipo-AKT2 KO n=3). J. Hepatic 
transcription levels following the clamp of genes regulated during in wild-type mice 
during a hyperinsulinemic-euglycemic clamp study (Control n=3, KO n=3).  
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Figure 3-6. 
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Figure 3-7. Mice with adipocyte-specific loss of Glut4 do not have 
hyperinsulinemia or glucose intolerance. A. PCR for Glut4 exon 10 from cDNA 
isolated from epididymal fat pads. B. Adipose tissue from male Adipo-Glut4 KO mice. C. 
Glucose tolerance tests at 1g/kg glucose IP were performed after an overnight fast in 
male and female control and Adipo-Glut4 KO mice (FeGlut4-Control n=7, Adipo-FeGlut4 
KO n=7, MGlut4-Control n=10, Adipo-MGlut4 KO n=8). D. Adipo-FeGlut4 KO, Adipo-
MGlut4 KO and control mice fasting insulin levels and 15 min post-glucose bolus insulin 
levels similar to control mice (FeGlut4-Control n=7, Adipo-FeGlut4 KO n=7, MGlut4-
Control n=9, Adipo-MGlut4 KO n=8). E. Male and female Adipo-Glut4 KO mice and 
control glucose homeostasis during an overnight fast and 2 hr meal challenge (FeGlut4-
Control n=7, Adipo-FeGlut4 KO n=9, MGlut4-Control n=10, Adipo-MGlut4 KO n=10). F. 
Adipo-FeGlut4 KO and Adipo-MGlut4 KO and control mice fasting and refed insulin 
levels during a 2 hr meal challenge (FeGlut4-Control n=7, Adipo-FeGlut4 KO n=9, 
MGlut4-Control n=9, Adipo-MGlut4 KO n=6). G. Insulin tolerance test of 0.75U/kg after a 
5 hour fast on male and female Adipo-Glut4 KO mice (FeGlut4-Control n=4, Adipo-
FeGlut4 KO n=3, MGlut4-Control n=9, Adipo-MGlut4 KO n=6). H. Insulin levels during 
ITT forcontrol and Adipo-FeGlut KO, Adipo-MGlut4 KO mice (FeGlut4-Control n=4, 
Adipo-FeGlut4 KO n=3, MGlut4-Control n=9, Adipo-MGlut4 KO n=6). 
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Figure 3-7. 
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Figure 3-8. Female mice with adipocyte-specific deletion of Glut4 do not have 
hepatic insulin resistance. A. Glucose infusion rate in Adipo-FeGlut4 KO mice during a 
clamp study (Control n=4, KO n=5). B. Whole body glucose disposal (Control n=4, KO 
n=5). C. HGP suppression during a clamp study (Control n=4, KO n=5). D. Insulin-
stimulated glucose uptake into brown adipose tissue (Control n=4, KO n=5). E. Insulin-
stimulated glucose uptake in skeletal muscle (Control n=4, KO n=5).  
 
Figure 3-8. 
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Figure 3-9. Male Adipo-Glut4 KO mice do not have insulin resistance. We clamped 
a cohort of male Adipo-Glut4 KO mice to compare to the Adipo-AKT2 KO mice. A. 
Glucose infusion rate in male control and Adipo-Glut4 KO mice. B. Glucose disposal in 
male control and Adipo-Glut4 KO mice. C. Hepatic glucose production in male control 
and Adipo-Glut4 KO mice. Shown as a scatter plot. (Control n=4, Adipo-Glut4 KO n=5). 
 
Figure 3-9. 
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Figure 3-10. Transcription of ChREBP and FASN are reduced in Adipo-AKT2 KO 
mice. A.Total ChREBP transcript levels in control and Adipo-AKT2 KO mice. B. 
Transcription levels of genes involved in de novo lipogenesis in control and Adipo-AKT2 
KO mice. C. cd36 (fatty acid transporter) expression levels in control and Adipo-AKT2 
KO mice. D. Adipose triglyceride lipase (ATGL) transcription levels in the fasted and 
refed state in control and Adipo-AKT2 KO mice. E. CGI-58, a coactivator of ATGL, 
expression levels in the fasted and refed state in control and Adipo-AKT2 KO mice. F. 
Expression levels of genes involved in de novo lipogenesis in control and Adipo-Glut4 
KO mice. (Control n=4, KO n=4 for all studies).  
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Figure 3-10. 
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Figure 3-11. Other published mechanisms of adipocyte insulin resistance are 
unchanged in Adipo-AKT2 KO mice. A. Transcription of retinol binding protein 4 
(RBP4) in control and Adipo-AKT2 KO mice. B. Fatty acid binding protein 4 (FABP4) 
expression in control and Adipo-AKT2 KO mice. C. Tumor necrosis factor alpha (TNFa) 
expression in control and Adipo-AKT2 KO mice. D. Glut1 expression in control and 
Adipo-AKT2 KO mice. E. Transcription levels of genes involved in redox potential in 
control and Adipo-AKT2 KO mice.  
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Figure 3-11. 
 
90	  
	  
CHAPTER 4: 
 
	  
Adipocyte Foxo1 deletion rescues brown fat in the 
Adipo-AKT KO, but has no effect on Adipo-AKT2 KO 
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Introduction 
 Mice without insulin signaling in mature insulin-responsive tissues liver, muscle 
and adipose exhibit dramatic decreases in these respective tissues, suggesting that 
insulin signaling is required for appropriate cell function (Boucher et al., 2016; Dong et 
al., 2006; Lu et al., 2012; O'Neill et al., 2015; Qiang et al., 2016; Shearin et al., 2016; 
Softic et al., 2016; Titchenell et al., 2015). A critical function of AKT in the adult liver and 
muscle is suppression of FOXO in response to insulin (Dong et al., 2008; Lu et al., 2012; 
O'Neill et al., 2016; Titchenell et al., 2015). The concomitant loss of FOXO in the 
absence of insulin signaling, has a dramatic effect on the phenotype observed in the 
liver and muscle, with normalization of suppression of hepatic glucose production in 
response to insulin in the hepatocytes and a rescue of the muscle atrophy observed in 
myocytes (Dong et al., 2008; Lu et al., 2012; O'Neill et al., 2016; Sandri et al., 2004; 
Titchenell et al., 2015). In adipose tissue, suppression of FOXO is also important for 
adipocyte differentiation, but it is unknown what role FOXO activity has in the mature 
adipocyte (Nakae et al., 2008; 2003; Yun et al., 2008). In 3T3L1s, some evidence 
suggests that FOXO1 may regulate lipolysis via transcription of ATGL (Chakrabarti and 
Kandror, 2009).  
 We wanted to know how adipocyte-specific deletion of Foxo1 would affect the 
loss of insulin-AKT signaling in our lipodystrophic Adipo-AKT KO model and insulin 
resistant Adipo-AKT2 KO model. We generated mice with the AdipoQ-Cre transgene 
and floxed for Akt1/Akt2/Foxo1 (TFKO). Surprisingly, we found that simultaneous 
deletion of FOXO1 in adipocytes rescues BAT but not WAT. These mice exhibit 
improvement in their glucose homeostasis during a meal challenge, and have less 
severe NAFLD, but remain insulin intolerant. In contrast, mice without adipocyte AKT2 
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do not have any improvement in their hyperinsulinemia during a 2 hour meal challenge 
when Foxo1 is deleted simultaneously (Adipo-FoxoAKT2 KO).  
 
Results 
Mice without Akt1/Akt2/Foxo1 have brown adipose tissue but not white adipose tissue 
 Deletion of Foxo1 simultaneously with Akt1 and Akt2 resulted in an interesting 
finding with no substantial rescue of WAT, but complete rescue of BAT (Figure 4-1A, B, 
C). The brown adipose tissue in this model is not wild-type in appereance, with 
increased lipid accumulation visible on H&E staining and a paler color of the tissue 
observed grossly (Figure 4-1C, D). The epididymal fat pad was slightly increased in 
sized compared to Adipo-AKT KO mice, but the brown adipose tissue, which is absent 
entirely the Adipo-AKT KO mice, was wild-type in size (Figure 4-1E). The liver of the 
TFKO model is significantly larger than control mice, but also significantly smaller than 
the Adipo-AKT KO mouse (Figure 4-1F).  
 
TFKO mice have improved glucose homeostasis compared to Adipo-AKT KO mice, but 
are insulin resistance  
 Similar to the Adipo-AKT KO mouse, the TFKO model has normal glucose 
tolerance but is hyperinsulinemic following a glucose bolus (Control = 1.1 ng/mL, TFKO 
= 8.4 ng/mL) (Figure 4-2A, B). While the TFKO mice maintain glucose homeostasis 
during a meal challenge, unlike the Adipo-AKT KO mice, there have elevated insulin 
levels compared to control mice (Control = 2.8 ng/mL, TFKO = 48.2 ng/mL) (Figure 4-
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2C, D). The persistent insulin resistance in TFKO mice is confirmed by an insulin 
tolerance test, during which they exhibit a blunted response to an insulin bolus (Figure 4-
2E). 
 
Mice with simultaneous adipocyte deletion of Akt2 and Foxo1 do not have decreased 
insulin levels in response to a meal challenge 
 With the improvement in glucose homeostasis and insulin sensitivity in the TFKO 
mice compared to the Adipo-AKT KO mice, and in the context of the data described over 
the last decade regarding AKT’s dominant role in regulating FOXO activity, we 
hypothesized that loss of Foxo1 may also improve the insulin resistance observed in the 
Adipo-AKT2 KO mouse. We generated mice with deletion of both Akt2 and Foxo1 
(Adipo-FoxoAKT2 KO). These mice have normal glucose tolerance (Figure 4-3A), and 
hyperinsulinemia during a meal challenge (Control = 1.6 ng/mL, Adipo-FoxoAKT2 KO = 
9.9 ng/mL). (Figure 4-3D) Surprisingly, this model does not exhibit fasting 
hyperinsulinemia (Control = 0.5 ng/mL, Adipo-FoxoAKT2 KO = 0.4 ng/mL) (Figure 4-3B, 
D). They also do not appear to suppress fatty acid levels in response to a meal (Control 
fasting = 2 mmol/L, Adipo-FoxoAKT2 KO fasting = 1.4 mmol/L, Control fed = 0.6 mmol/L, 
Adipo-FoxoAKT2 KO = 1.2 mmol/L) (Figure 4-3E). In the refed state, the transcription 
levels of the DNL program is reduced in Adipo-FoxoAKT2 KO mice compared to control 
mice, but interestingly, they appear to be increased in the fasted state in mice with Foxo 
deletion alone in the adipocyte (Figure 4-3F, G). 
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Discussion 
FOXO has well-described functions as part of the insulin signaling-AKT axis in 
liver, especially, and also in muscle ((Dong et al., 2008; Lu et al., 2012; O'Neill et al., 
2016; Sandri et al., 2004; Titchenell et al., 2015). However, it’s role in adipose tissue 
remains elusive, though some evidence suggests it is critical to not only adipogenesis, 
but also the function of mature adipose tissue ((Chakrabarti and Kandror, 2009; Nakae 
et al., 2008; 2003). We asked how concurrent deletion of Foxo1 altered the phenotype of 
both the lipodystrophic Adipo-AKT KO model and the insulin resistant Adipo-AKT2 KO 
model. Surprisingly, we found that BAT is rescued in the lipodystrophic model when 
Foxo1 is deleted, but WAT tissue remains largely unaffected (Figure 4-1). This suggests 
that deletion of Foxo1 may affect BAT homeostasis more robustly than WAT, consistent 
with the rescue of muscle atrophy observed in the IR/IGF-1R/Foxo1 muscle-specific 
knockout model, as brown adipocytes and myocytes share a common origin (O'Neill et 
al., 2016; Rosen and Spiegelman, 2014). The function of FOXO specifically in brown 
adipose tissue remains to be elucidated, but these data suggest it may have an integral 
function in BAT maintenance or differentiation distinct from its function in white adipose 
tissue. 
Interestingly, both models exhibit an improvement in fasting insulin levels 
compared to the Adipo-AKT KO and Adipo-AKT2 KO, but neither the TFKO or the 
Adipo-FOXOAKT2 KO has normal plasma insulin levels in response to a 2 hour meal 
challenge and the Adipo-FoxoAKT2 KO still has increased circulating free fatty acids 
(Figure 4-2D, 4-3D, E). Based on these data, we concluded that deletion of Foxo1 did 
not dramatically alter the insulin resistance that Adipo-AKT2 KO mice exhibit. However, 
the potential improvement in fasting insulin levels may indicate that loss of FOXO in BAT 
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is affecting the metabolism of this tissue in the Adipo-AKT2 KO mouse and allowing it to 
serve as a glucose energy sink even when HGP is increased, protecting this model from 
fasting hyperinsulinemia, but not sufficient to improve insulin resistance when the system 
is more rigorously challenged with stimuli. This is consistent with the ability of BAT to 
take up high levels of glucose, at least 10x the glucose uptake observed in WAT in the 
basal state, and nearly 40x the insulin-stimulated glucose uptake (Jenkins et al., 1988). 
Future work is needed to determine if and how the BAT may be protecting the body 
against fasting hyperinsulinemia and potentially some level of hepatic insulin resistance. 
However, if this hypothesis is true, it could have implications for the treatment of T2D by 
increasing the volume or respiratory capacity of BAT in humans, which have been 
shown to have functional BAT, expressing uncoupling protein-1 (UCP-1), and though the 
quantity of BAT is much less in humans than rodents, human BAT has the same 
respiratory capacity per mitochondria as rodent BAT (Porter et al., 2016).  
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Figure 4-1. Mice without Akt1/Akt2/Foxo1 have brown adipose tissue but not white 
adipose tissue. A. Epididymal fat from control and TFKO mice. B. Intrascapular fat from 
control and TFKO mice, no white adpose intrascapular fat is observed in TFKO mice. C. 
Brown adipose tissue in control and TFKO mice is of similar size. D. Epididymal fat is 
increased in TFKO compared to Adipo-AKT KO mice, but not to wild-type levels. Brown 
adipose tissue is of the same size as control mice. E. TFKO mice have hepatomegaly 
but not to the extent of Adipo-AKT KO mice. Control n=5, TFKO n=6, Adipo-AKT KO n=4 
for all groups.  
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Co
ntr
ol
TF
KO
F1
2K
O
0
5
10
15
%
 b
od
y 
w
ei
gh
t
Ep
. W
AT BA
T
Pa
nc
rea
s
He
art
Sp
lee
n
Ki
dn
ey
0.0
0.5
1.0
1.5
2.0
%
 b
od
y 
w
ei
gh
t
Control
TFKO
F12KO
A.
B.
C.
D.
E. Organ weights 
(% body weight)
F. Liver weight (% body weight)
*
*
*
*
Control
Control
Control
Control
TFKO
TFKO
TFKO
TFKO
98	  
	  
Figure 4-2. TFKO mice have improved glucose homeostasis compared to Adipo-
AKT KO mice, but are insulin resistance.  A. Glucose tolerance test after an overnight 
fast and challenged with 1g/kg IP in control and TFKO mice. B. Fasting insulin and 15 
min post-glucose injection insulin levels in control and TFKO mice.  C. Blood glucose 
levels after an overnight fast and 2 hour meal challenge in control and TFKO mice. D. 
Plasma insulin levels after an overnight fast and 2 hour meal challenge in control and 
TFKO mice. E. Insulin tolerance test after a 5 hour fast and injected with 0.75U/g insulin 
in control and TFKO mice. Control n=5, TFKO n=6 for all groups.  
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Figure 4-3. Mice with simultaneous adipocyte deletion of Akt2 and Foxo1 do not 
have decreased insulin levels in response to a meal challenge. A. Glucose 
tolerance test on Adipo-FoxoAKT2 KO mice after an overnight fast and injected with 
1g/kg glucose. B. Plasma insulin levels at basal and 15 min time points during glucose 
tolerance test. C. Blood glucose levels after an overnight fast and 2 hour meal challenge 
in Adipo-FoxoAKT2 KO mice. D. Plasma insulin levels corresponding to the overnight 
fast and 2 hour meal challenge. E. Plasma FFAs levels after an overnight fast and 2 
hour meal challenge in Adipo-FoxoAKT2 KO mice. (Control n=6, Adipo-FoxoAKT2 KO 
n=7 for all groups.) F. Transcript levels of genes involved in DNL from epididymal fat 
pads in the fed state in Adipo-FoxoAKT2 KO and control mice (Control n=3, Adipo-
FoxoAKT2 KO n=3). G. Transcript levels of genes involved in DNL from epididymal fat 
pads in the fasted state in Adipo-Foxo KO mice (Control n=2, Adipo-Foxo KO n=2). 
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Figure 4-3. 
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CHAPTER 5: 
 
Summary and Speculation 
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5.1 AKT is required for adipocyte function 
Lack of AKT causes a lipodystrophy 
 Mice without AKT1 or AKT2 (Adipo-AKT KO) have a profound lipodystrophy 
(Figure 2.1). This model has fasting hyperinsulinemia, aberrant glucose homeostasis in 
response to a meal challenge, and NAFLD. The lack of the different adipose depots may 
be the result of a distinct requirement of AKT during adipocyte maintenance rather than 
its requirement for adipogenesis. In the inguinal fat pad, adiponectin is expressed during 
development, while this does not appear to be true in the epididymal fat pad, and the 
expression profile in BAT is unknown (Hong et al., 2015). Previous work argues that 
suppression of Foxo activity is the main mechanism for the requirement for AKT during 
adipogenesis (Nakae et al., 2003; Yun et al., 2008). This may be the reason the inguinal 
depot does not develop in the Adipo-AKT KO mouse, but it is unlikely this explains the 
lack of epididymal fat. We argue that AKT is also required for adipocyte maintenance 
through an unknown mechanism. Potentially, the adipocyte could differentiate normally 
and simply does not maintain its lipid droplet and does not function or appear to be a 
mature adipocyte. An alternative hypothesis is that at the end stage of differentiation, 
when the AdipoQ-Cre is likely on, lipid accumulation is required for completion of 
adipogenesis and if the adipocyte is unable to accumulate lipids, differentiation cannot 
be completed. Either of these hypotheses could explain the size, immune infiltrate, and 
fibrosis of the epididymal adipose depot (Figure 2.1).  
One question that remains is why does hepatic insulin resistance develop in this 
model? If we suggest that a non-canonical pathway exists in the liver that promotes 
hepatic glucose production and is regulated peripherally by adipose tissue, how is this 
pathway regulated in the absence of adipose tissue? Indeed, low fasting plasma FFAs 
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levels are observed in the Adipo-AKT KO mouse, which we interpret as their inability to 
upregulate fatty acids in response to a fast because they have so little adipose tissue to 
undergo lipolysis (Figure 2.4). The most likely explanation for this paradox is that 
because the liver is capable of storing and hydrolyzing lipid species, in the absence of 
adipose tissue and the presence of extreme NAFLD, the excess accumulation of 
triglyceride in the liver can drive hepatic glucose production. In this state of high levels of 
energy accumulation in the liver, glucose homeostasis regulation is defective when 
challenged with a meal (Figure 2.4). It is surprising that glucose homeostasis is not 
affected during a glucose tolerance test, but is likely the results of hyperinsulinemia 
compensating efficiently and the challenge being less burdensome than a meal 
challenge (Figure 2.4). Additionally, it is likely the Adipo-AKT KO mice consume high 
quantities of food on a refeeding because this model’s low leptin levels, preventing 
regulation of satiety observed in control mice (Figure 2.1). All three serum adipokines 
measured, leptin, adiponectin, and resistin, were very low (Figure 2.1). An absence of 
leptin is likely a leading contributor to the insulin resistance in this model, as leptin 
replacement is known to rescue insulin resistance in other models of lipodystrophy (W. 
S. Chen et al., 2009; CortEs et al., 2014; Gray et al., 2006; Shimomura et al., 1999). The 
loss of adiponectin may contribute to the insulin resistance in this model, though 
evidence of the requirement for adiponectin to maintain insulin sensitivity is dubious (K. 
Ma et al., 2002; Maeda et al., 2002; Nawrocki, 2005).  
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The AKT-Foxo axis controls the presence of brown adipose tissue, but not white adipose 
tissue 
 We generated a model without adipose AKT or FOXO1 (TFKO). This mouse 
does not have dramatically more WAT, but the presence of BAT is preserved. These 
mice are still insulin intolerant and exhibit hyperinsulinemia, but manage their glucose 
homeostasis more efficiently and for reasons that are unclear, appear to not have fasting 
hyperinsulinemia. They still display NAFLD and their BAT tissue has more lipid 
accumulation compared to controls (Figure 4-1). This surprising finding suggests that 
suppression of FOXO1 is sufficient for BAT maintenance or development, but does not 
improve WAT function. Given that BAT has a different developmental path, 
differentiating from the same precursors as myocytes, it may not be surprising that the 
AKT-FOXO axis plays different roles in BAT compared to WAT, but the requirement for 
FOXO suppression and the role of FOXO in BAT tissue is largely undefined. Recent 
work in muscle has shown that deletion of Foxo simultaneously with insulin receptor and 
IGF-1R rescues the proteolysis and muscular atrophy observed in myocytes when 
insulin signaling is ablated (O'Neill et al., 2016). Potentially the BAT tissue in the Adipo-
AKT KO mouse also atrophies and Foxo deletion is able to at least partially reduce this.  
 Interestingly, Foxo1 deletion does not rescue the presence of WAT. Why the 
presence of WAT is lost in the Adipo-AKT KO is unknown, but maintenance of adipose 
tissue is dependent on lipid accumulation, and without AKT present in the cell, nutrient 
uptake, growth, de novo lipogenesis, re-esterification, and suppression of lipolysis may 
be ablated, resulting in a complete inability to store energy, and thus maintain a cell as 
an adipocyte. Based on the TFKO results, it appears that FOXO1 does not play a 
dominant role in the storage of energy in WAT.  
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5.2 Adipocyte Akt1 is dispensable for systemic insulin sensitivity 
 We show that mice with adipocyte-specific deletion of Akt1 have normal glucose 
tolerance and insulin sensitivity (Figure 3-1). This mirrors the results of the insulin 
sensitivity phenotype observed in the Akt1 null mouse (Cho et al., 2001). Interestingly 
though, Akt1 null mice are protected from diet-induced obesity, consistent with their 
smaller body size, suggesting that Akt1 in the adult may still be required for 
accumulation of adipose mass (Wan et al., 2011a). In this thesis, the Adipo-AKT1 KO 
model was not interrogated for changes in energy expenditure or protection from insulin 
resistance. Potentially adipocyte AKT1 controls the energy expenditure changes 
observed in the Akt1 null mouse. If this is indeed the case, studies using an inducible 
AdipoQ-Cre transgene in the adult, or the BAT specific promoter UCP-1-Cre could 
determine which adipose depots are involved in the AKT1-dependent regulation of 
energy expenditure.  
 
5.3 Adipocyte Akt2 controls systemic metabolism 
Adipocytes without AKT2 are insulin resistant 
 Adipocytes lacking AKT2 have a defect in insulin-stimulated glucose uptake 
(Figure 3-2D, Figure 3-5G). By this measure, these adipocytes are insulin-resistant. Yet 
surprisingly, the majority of downstream signaling in the epididymal fat pad remains 
intact, with phosphorylation of FOXO1 and PRAS40 intact and dephosphorylation of 
HSL also normal. A defect in dephosphorylation of Perilipin is observed in a preliminary 
blot. What is not yet known is the adipocyte-autonomous suppression of lipolysis in 
response to insulin. Several methods can be employed to measure this, but one method 
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likely to generate useful data is isolation of primary adipocytes from control and Adipo-
AKT2 KO mice to stimulate with isoproterenol and suppress with insulin. This will allow 
adipocyte-specific release of glycerol and FFAs to be measured, establishing the cell-
autonomous effect on the lipolysis cascade in the Adipo-AKT2 KO model. 
 
Free fatty acids regulate hepatic glucose production 
 The model of selective insulin resistance proposed in 2008 by Brown and 
Goldstein proposes that regulation of hepatic gluconeogenesis and de novo lipogenesis 
diverge downstream of the insulin receptor, explaining why hepatic insulin sensitivity is 
retained in regards to DNL, but lost for the suppression of HGP (Brown and Goldstein, 
2008). Work from us and other labs have proposed a model through which insulin 
sensitivity in the periphery, specifically adipose tissue, regulates HGP in the absence of 
insulin signaling (Perry et al., 2015; Titchenell et al., 2016). The work presented in this 
thesis suggests that even in the presence of canonical insulin signaling in the liver, FFAs 
can promote HGP. To more directly address this question, clamp studies at much higher 
insulin doses could be performed to overcome adipose insulin resistance generated from 
lack of AKT2 and measure whether HGP is subsequently suppressed.  
 Without AKT2 in the adipose tissue, it is possible that further reduction of plasma 
FFAs levels, regardless of insulin dose, cannot be achieved. One interpretation of the 
data presented in Chapter 3 of this thesis, is that in the presence of canonical insulin 
signaling, HGP can be suppressed at high insulin levels without suppression of FFAs. 
During a refeed challenge, insulin levels are nearly three times higher in the Adipo-AKT2 
KO mouse than the insulin levels achieved during the clamp study. However, portal 
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insulin levels are generally considered to be three times higher than peripheral 
measures when insulin is secreted from the pancreas, as most insulin never leaves the 
liver (Edgerton et al., 2006). During a clamp study, when peripheral insulin is given and 
release of insulin from the pancreas is inhibited, peripheral and portal insulin levels are 
considered similar (Edgerton et al., 2006). By this calculation, when Adipo-AKT2 KO 
mice are challenged with a meal, portal insulin levels would be nearly 25 ng/mL in the 
Adipo-AKT2 KO mouse, compared to ~6 ng/mL in control mice, and almost ten times 
higher than the insulin concentration during the clamp study. This may explain why HGP 
cannot be suppressed during a clamp study, but glucose homeostasis by other 
measures is normal (Figure 3-1, 3-3). It is important to note that even though glucose 
homeostasis is normal during a refeed challenge but not clamp, the percent suppression 
of FFAs levels is the same under both conditions. With a three fold increase in peripheral 
insulin concentration during the refeed challenge compared to the clamp, thirty-six to 
forty percent suppression of FFAs may represent maximal suppression of FFAs in the 
absence of adipocyte AKT2 signaling. In fact, that percent of FFAs suppression is 
consistent across all measures taken: refeed challenge, insulin tolerance test, and 
hyperinsulinemic-euglycemic clamp (Figure 3-1, 3-3). One experimental design that 
could be utilized would be suppression lipolysis through a pathway other than the insulin 
signaling cascade. Lactate also suppresses lipolysis and a lactate receptor agonist could 
reduce circulating FFAs acutely during a clamp study, allowing us to ask if HGP is then 
suppressed (Sakurai et al., 2014).  
Mechanistically, the perturbations in the liver that must occur for HGP promotion 
in the presence of canonical insulin signaling remain unknown. In the absence of 
canonical insulin signaling, it is clear the pathway regulated by the periphery is able to 
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dominate in regards to gluconeogenesis (Titchenell et al., 2016). Perry, et al (2015) 
argue that accumulation of hepatic Acetyl-CoA drives gluconeogenesis in hepatocytes, 
resulting in a pathway that overrides insulin signaling (Perry et al., 2015). Indeed, this is 
possible, and they show that administering acetate to wild type animals is sufficient to 
inhibit suppression of HGP by insulin (Perry et al., 2015). However, it is not clear if 
endogenous substrates like triglyceride are able to produce the same effect, and if so, 
whether or not Acetyl-CoA is the product of hepatic metabolism responsible.  
 
The timeline of systemic insulin resistance in Adipo-AKT2 KO mice 
 In models of diet-induced insulin resistance, and perhaps most obviously in 
human patients, an obvious decrease in hepatic insulin sensitivity takes time to develop. 
In rodent and dog models, sensitive measures  such as the hyperinsulinemic-euglycemic 
clamp can detect changes in insulin sensitivity by 3 weeks, but glucose intolerance 
occurs at much slower pace (Park et al., 2005a; Rocchini et al., 1997). Some studies 
have shown that feeding rats HFD for 3 days was sufficient to induce hepatic IR but not 
peripheral IR, suggesting that the onset of hepatic IR occurs in the liver as a result of 
hepatic triglyceride accumulation and is not determined by peripheral insulin signaling 
aberrations (Kraegen et al., 1991; Samuel et al., 2004). Other studies, however, have 
dissociated NAFLD from insulin resistance in both humans and rodent models 
(Benhamed et al., 2012; George, 2004; Monetti et al., 2007). Fatty liver alone does not 
appear to be sufficient to cause IR, but rather the potential pathways affected by 
accumulated trigclyeride and trafficking of triglycerides and cholesterols to other organs 
may play a critical role, rather than accumulation alone. The Adipo-AKT2 KO mice show 
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only a trend towards increased liver triglyceride levels, despite their apparent hepatic 
insulin resistance (Figure 3-5).  
The rate at which insulin resistance can be induced by adipocyte-specific 
deletion of Akt2 is left unanswered in this work. Models with inducible adipocyte 
recombination have several complicating factors. Tamoxifen-inducible AdipoQ-CreER is 
available, but tamoxifen injection alone induces a lipodystrophy and upon withdrawal, a 
regenerative adipogenesis is observed (Ye et al., 2015). This would be complicated to 
interpret with the Akt2 floxed mouse because it is known that in the adult animal, Akt2 is 
required for adipogenesis. Mice with platelet-derived growth factor receptor alpha 
(PDGFRα)-Cre crossed with Akt2 floxed mouse have a defect in HFD-induced 
adipogenesis. This does not necessarily indicate a direct adipocyte function of Akt2 in 
the adult requirement for adipogenesis because PDGFRα is expressed not only in the 
stromal vascular fraction and adipocyte precursors of the adipose depot, but also the 
brain and other organs that may impact adipogenesis (Berry and Rodeheffer, 2013; 
Jeffery et al., 2014; 2015).  
A doxycycline-inducible AdipoQ-Cre has also been generated and is a useful tool 
for mature adipocyte deletion in white adipose depots (Shao et al., 2016; Q. A. Wang et 
al., 2015). However, this Cre does not delete efficiently in BAT, though that does not 
negate the possibility that a robust phenotype might be generated by deleting Akt2 
largely in white adipose depots only, and may result in interesting distinctions between 
AKT2 functions in WAT versus BAT. This may also answer the question of how rapidly 
systemic insulin resistance is induced when Akt2 is lost. If this happens rapidly, it would 
provide an understanding of the critical role of WAT AKT2 in maintaining energy 
homeostasis and also may provide information in regards to the mechanism through 
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which hepatic insulin resistance develops in the Adipo-AKT2 KO mouse. Alternatively, 
other organs, especially BAT if functional AKT2 is present, may compensate and 
development of insulin resistance may occur at a rate similar to diet-induced IR.  
 
5.4 The adipocyte mechanism(s) that propagate insulin resistance 
Glucose uptake, DNL, re-esterification and other potential contributors of systemic 
insulin resistance 
The fundamental question unanswered by the work presented in this thesis is: 
what is the adipocyte-centric mechanism for controlling circulating FFAs? We provide 
convincing evidence that glucose uptake is unlikely to account for the systemic insulin 
resistance we observe in the Adipo-AKT2 KO mice, with every measurement taken from 
the Adipo-Glut4 KO mice matching the values of their control littermates, from glucose 
tolerance, insulin tolerance, and hyperinsulinemic-euglycemic clamp, except for a defect 
in glucose uptake and glucose infusion rate likely accounted for by the defect in adipose 
tissue uptake alone (Figure 3-5). The ability of Adipo-Glut4KO mice to suppress hepatic 
insulin resistance is clear, while the complete inability of the Adipo-AKT2 KO mice to do 
so is also evident (Figure 3-3, 3-5). Mice without adipocyte AKT2 have a more 
pronounced decrease in glucose infusion rate and whole body glucose uptake, as well 
as a likely defect in muscle-specific glucose uptake, suggesting a systemic effect on 
insulin sensitivity that is not observed in the Adipo-Glut4 KO model (Figure 3.5).  
The prevailing model in the literature is that a defect in glucose uptake causes a 
decline in de novo lipogenesis, and thus a failure to appropriately sequester fatty acids, 
or even potentially to make insulin-sensitizing lipids (Herman et al., 2013; Moraes-Vieira 
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et al., 2016; Tang et al., 2016; Yore et al., 2014). While some members of the DNL 
program are decreased in Adipo-AKT2 KO mice, it is not consistent, with only ChREBP 
and FAS being significantly downregulated. SREBP1c, ACC, and ACLY are expressed 
at control levels (Figure 3-10). Thus, DNL may be defective in the adipose tissue of 
these mice, consistent with observations that adipose IR and decreased DNL correlate 
(Eissing et al., 2013; Roberts et al., 2009). Interestingly, the Adipo-Glut4 KO model does 
not exhibit defects in DNL gene expression, suggesting that ablating glucose uptake 
alone with intact adipocyte insulin signaling is not sufficient to cause downregulation of 
DNL (Figure 3-10). It is entirely possible that regulation of DNL is coordinated between 
insulin signaling and glucose uptake, consistent with data showing that increasing 
glucose uptake increases DNL in the adipocyte (Herman et al., 2013; Moraes-Vieira et 
al., 2016). It is unknown how ChREBP is regulated in response to insulin, and previous 
work using aP2-Cre deletion of Glut4 suggested that ChREBP was regulated largely in 
response to glucose uptake, but this data is confounded by more recent working 
showing aP2-Cre is promiscuously expressed. The data presented here suggest that 
ChREBP is regulated in response to insulin-AKT2 signaling, independent of glucose 
uptake. Additionally, mTORC1 signaling may be intact when AKT2 is lost in adipocytes, 
preserving expression of SREPB1c and its target genes.  
The work presented here in no way contradicts evidence that improved glucose 
uptake increases de novo lipogenesis and thereby improves insulin sensitivity, but the 
mechanism through which this occurs is not well defined. It is not known if the rate-
limiting step is glucose uptake and that whether this glucose it utilized for re-
esterification of fatty acids or DNL is limited by the fatty acids available for re-
esterification, and thus improved glucose uptake results in more sequestered fatty acids 
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independent of the downstream pathway. The re-esterification pathway is more 
dependent on glucose uptake than insulin stimulation, and thus re-esterification is likely 
reduced in both the Adipo-AKT2 KO mouse and the Adipo-Glut4 KO mouse Figure 3-2, 
3-3, 3-8) (Lisch et al., 1973). In wild-type adipose tissue, glucose uptake and 
glyceroneogenesis is rate-limiting, with overexpression of PEPCK promoting re-
esterification in adipocytes (Franckhauser et al., 2002; Reshef et al., 2003). Given the 
equivalent decrease in insulin-stimulated glucose uptake between the Adipo-AKT2 KO 
model and Adipo-Glut4 KO model, we conclude that the defect in glucose uptake and 
blunted re-esterification is not sufficient to promote systemic insulin resistance.  
Several other mechanisms have been proposed to explain the difference in 
insulin sensitivity between the aP2-Cre Glut4 KO mouse and the aP2-Glut4 over-
expressing mouse. We investigated these mechanisms: elevated retinol binding protein 
4 transcription levels and decreases in redox potential regulated transcriptionally (Kraus 
et al., 2015; Yang et al., 2005). No changes were observed in the Adipo-AKT2 KO 
adipocyte relating to these published mechanisms (Figure 3-11).  
Circulating leptin and resistin levels are normal in the Adipo-AKT2 KO mouse 
and thus are unlikely to contribute to the observed systemic insulin resistance. Plasma 
adiponectin levels are decreased by ~40%, and thus may play a role, albeit minor, in the 
hepatic insulin resistance (Figure 3-3A). Mice null for adiponectin have varied 
phenotypes, with one group reporting insulin resistance, and other groups finding no 
changes in insulin sensitivity on normal chow (K. Ma et al., 2002; Maeda et al., 2002; 
Nawrocki, 2005). Therefore, it is unlikely that a 40% decrease in adiponectin levels 
would result in the severity of insulin resistance we observe in the Adipo-AKT2 KO 
mouse.  
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Akt-Foxo axis does not control circulating free fatty acids 
 Much data have accumulated in regards to the liver that a central function of AKT 
in response to insulin is to deactivate FOXO, and that concomitant deletion of Foxo 
rescues a portion of the effects from loss of insulin receptor-AKT signaling (Dong et al., 
2008; Lu et al., 2012; Titchenell et al., 2015). We asked the same question in the Adipo-
AKT2 KO mouse, by generating an Adipo-FoxoAKT2 KO double knockout model. 
Simultaneous loss of adipocyte Foxo did not rescue the hyperinsulinemia observed in 
the Adipo-AKT2 KO mouse following a meal challenge (Figure 4-3). Interestingly, 
adipocyte loss of FOXO alone appeared to increase the transcription of the DNL gene 
program in the fasted state, when DNL would normally be inactive (Figure 4-3). 
However, when the adipose of the double FOXO-AKT2 KO was queried for changes in 
DNL, they were not rescued compared to the Adipo-AKT2 KO mouse (Figure 4-3). In 
fact, SREBP1c transcription levels appear to be decreased and transcription levels of 
ACLY and ACC were also decreased, suggesting a more dramatic reduction in the DNL 
program in the Adipo-FoxoAKT2 adipose tissue than the Adipo-AKT2 mouse (Figure 4-
3). This data is preliminary, with a small n, but may indicate that FOXO does regulate 
DNL, likely through indirect mechanisms, as no evidence thus far suggests that Foxo 
functions as a transcriptional repressor. Considering the role of adipose tissue in the 
fasted and fed states is different than the role of liver and muscle, it stands to reason 
that the downstream effectors of insulin signaling, such as FOXO, while conserved 
genetically, may have distinct functions.  
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Lipolysis is likely the key regulator of circulating free fatty acid levels 
  We argue that a defect in insulin suppression of lipolysis is likely in Adipo-AKT2 
KO mice. Primary adipocytes made from BAT of Akt2 null mice show a defect in their 
ability to suppress lipolysis (Koren et al., 2015). This model is also unable to fully 
suppress fatty acids and glycerol release in response to an insulin bolus or during 
hyperinsulinemic-euglycemic clamp (Koren et al., 2015). In the Adipo-AKT2 KO mice, a 
blunting of insulin-mediated suppression of circulating FFAs is observed in response to a 
meal, an insulin bolus, and during hyperinsulinemic-euglycemic clamp (Figures 3-1, 3-3). 
These data indicate a physiological defect in suppression of lipolysis. Within the adipose 
tissue, de-phosphorylation of hormone-sensitive lipase (HSL) is normal in response to a 
meal challenge, but a defect in de-phosphorylation of Perilipin appears to be present, but 
needs to be confirmed in additional individuals (Figure 3-2). This suggests that while 
very little HSL is active in the fed state, it has access to the lipid droplet even at this time 
of hyperinsulinemia and high nutrient load. The appropriate de-phosphorylation of HSL is 
consistent with either an AKT-independent pathway regulating lipolysis, or the low levels 
of AKT1 present, which are unchanged in the Adipo-AKT2 KO mouse, may be sufficient 
to compensate for the loss of AKT2 (Figure 3-2). If the de-phosphorylation of ATGL is 
normal remains to be elucidated.  
 
Blunted fatty acid uptake may contribute to elevated circulating FFAs 
While a defect in suppression of lipolysis in response to insulin would account for 
the elevated FFAs in the Adipo-AKT2 mouse, there is another possible mechanism that 
could account for or contribute to this: fatty acid uptake in the adipocyte in response to 
116	  
	  
insulin. We show that transcriptional expression of cd36, the fatty acid transporter (FAT) 
is expressed at normal levels in the adipose tissue of the Adipo-AKT2 KO mouse, but we 
did not query the trafficking of cd36 to the plasma membrane in response to insulin. 
Thus, it is possible that insulin-stimulated fatty acid uptake may be defective. Mice null 
for cd36 exhibit a defect in suppression of HGP during hyperinsulinemic-euglycemic 
clamp, but have normal glucose infusion rates and normal whole-body glucose uptake. 
Interestingly, their basal glucose uptake was increased compared to control mice, but 
normal during the insulin portion of the clamp (Vroegrijk et al., 2013). In nutrient-poor 
conditions, muscle activates cd36 to take up fatty acids. Blunting of this may make 
muscle more dependent on glucose and could account for the increased basal glucose 
uptake in this model (Vroegrijk et al., 2013). Knockdown of cd36 in 3T3L1 adipocytes 
implies a reciprocal regulation between fatty acid uptake and lipolysis, with a decreased 
ability to take up fatty acids suppressing lipolysis (D. Zhou et al., 2012). Thus, a potential 
feedback loop may exist in the adipocyte between fatty acid uptake regulation and the 
control of lipolysis. Based on our current understanding, it does not appear that loss of 
cd36 trafficking in the adipocyte alone could account for the severity of insulin resistance 
observed in the Adipo-AKT2 KO mouse.  
 
Does the AKT-mTORC1 axis control circulating free fatty acid levels? 
Most lines of evidence lead us to the conclusion that insulin is unable to fully 
suppress lipolysis in the Adipo-AKT2 KO mouse. This may be the result of incomplete 
de-phosphorylation of Perilipin. However, we do not understand how AKT2-dependent 
de-phosphorylation of Perlipin occurs. Is there a defect in the energy balance of 
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adipocytes in this model? cAMP levels have not been measured and may be increased, 
affecting activity of PKA. Is the phosphorylated Perilipin in fact at the lipid droplet or do 
we see a difference in lipid droplet de-phosphorylation compared to whole-cell de-
phosphorylation? Is it possible that mTORC1 inactivation is incomplete in the Adipo-
AKT2 KO adipocyte, either because of changes in energy balance or because of 
incomplete insulin signaling? Recent work has found that PKA directly phosphorylates 
mTORC1 in a β-adrenergic signaling dependent event, and while they interpret that work 
in the context of thermogenic responsiveness, it has implications for the regulation of 
lipolysis, especially considering that these mice also have a lipodystrophy (D. Liu et al., 
2016). Evidence from Chakrabarti, et al (2009, 2013) have suggested the Atgl 
expression can be regulated in 3T3L1s by Foxo and mTORC1 (Chakrabarti et al., 2013; 
Chakrabarti and Kandror, 2009). No changes in Atgl transcription were observed in the 
Adipo-AKT2 KO adipose tissue (Figure 3-10), but mTORC1, with its diverse functions, 
could play an unexplained role in regulation of ATGL or Perilipin activity.  
Still another study has shown that mice without adipocyte raptor are insulin 
resistant (P. L. Lee et al., 2016). These mice do not have the same degree of insulin 
resistance as the Adipo-AKT2 KO mice, most likely because the adipocyte Raptor KO 
model likely has normal glucose uptake, or potentially increased glucose uptake, as an 
upregulation of AKT phosphorylation is noted as well as increase in the DNL 
transcription program. This model dissociates the DNL normally correlated with 
adipocyte IR, suggesting that the decrease in the DNL genetic program is not required 
for insulin resistance. Therefore, the insulin resistance is most likely the result of plasma 
lipid species being increased. The authors did not ask how FFAs are regulated in 
response to insulin or a meal, but show that triglycerides and cholesterol are elevated in 
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the ad libitum state (P. L. Lee et al., 2016). FFAs are not significantly elevated under ad 
lib conditions in the Adipo-AKT2 KO model (Table 3-1). An alternative hypothesis is that 
mTORC1 regulates insulin sensitivity in a pathway parallel to AKT2 and that the insulin 
resistance in the Adipo-AKT2 KO mouse is not a result of a decrease in mTORC1 
activity.  
Interestingly, adipocyte-specific deletion of rictor yields an insulin resistant 
phenotype similar but less severe than observed in the Adipo-AKT2 KO mouse. While 
the authors interpret the Adipo-Rictor KO phenotype as being due solely to the loss of 
glucose uptake and downregulation of DNL, this model also has a defect in insulin-
mediated suppression of FFAs (Tang et al., 2016). It is possible that AKT2 is the link 
between the mTORC2 and mTORC1 loss of function models, with mTORC2 being 
required for maximal AKT2 function, yielding defects in glucose uptake and suppression 
of lipolysis, and a necessary downstream effect of mTORC2-AKT2 signaling ablated in 
the mTORC1 KO model. The Adipo-AKT2 KO mouse may have a more severe insulin 
resistance phenotype than the Adipo-Raptor KO because the latter model is likely able 
to compensate for the systemic disruption of energy balance with improved glucose 
uptake, consistent with both its increased AKT phosphorylation and elevated DNL 
transcriptional program. One potential experiment to address the question of the role of 
mTORC1 might be the development of an AdipoQ-Cre AKT2-TSC double knockout 
mouse, to activate mTORC1 in the absence of Akt2 signaling. Given our elimination of 
the hypothesis that the AKT2-FOXO axis controls lipolysis in the Adipo-AKT2 KO 
mouse, the other major target of AKT signaling, mTORC1, warrants further investigation.  
A critical experiment that might directly address the role of lipolysis regulation in 
the Adipo-AKT2 KO model would be to compromise lipolytic activity in vivo. Utilizing a 
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floxed allele of Atgl, perilipin, or Hsl might address this question. Especially in the case 
of perilipin and Hsl, which are required for lipolysis, a model without adipocyte AKT2 and 
heterozygous for a floxed allele might rescue any defects in lipolysis without resulting in 
a complex phenotype that would be difficult to interpret, thus informing our 
understanding of the role of lipolysis in the propagation of insulin resistance from the 
adipocyte to the muscle and liver.  
 
Concluding remarks 
 The study of insulin resistance and Type 2 Diabetes mellitus and the generation 
of models for these diseases has focused largely on the liver, with an advanced 
understanding of hepatic insulin signaling resulting. We know that disruption of hepatic 
insulin signaling at the level of the insulin receptor, AKT, or downstream effectors alters 
systemic insulin sensitivity. This work has vastly improved our future ability to target 
hepatic insulin resistance, as we now possess an understanding of the functions of 
various components of insulin signaling in the liver. Previously, we have lacked models 
for the study of insulin signaling in the adipocyte, inhibiting our ability to understand what 
effects of insulin signaling in the adipocyte are best targeted for the development of 
therapeutics. This work has shown that disrupted insulin signaling in the adipocyte is 
sufficient to cause systemic insulin sensitivity, not through the previously proposed 
defect in adipocyte glucose uptake, but rather because of the resulting increased 
circulating FFAs. These elevated FFAs are likely a result of insulin resistance in the 
adipocyte leading to an inability to fully suppress lipolysis (Figure 5-1). Potentially, this 
defect in lipolysis suppression is mediated by incomplete de-phosphorylation of Perilipin 
(Figure 3-2), and an AKT2-Perilipin axis may control suppression of adipocyte lipolysis 
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through a mechanism not yet understood. With this evidence of the importance of 
suppressing FFAs in response to insulin, we have improved our understanding of the 
adipocyte mechanisms that can lead to systemic insulin resistance. In the future, a 
therapeutic focus on adipocyte insulin sensitivity, insulin-mediated suppression of 
lipolysis, and decreased circulating FFAs may improve our ability to treat insulin 
resistance and Type 2 Diabetes mellitus.  
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Figure 5-1. A proposed model for how adipocyte-specific loss of AKT2 leads to systemic 
insulin resistance.  
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CHAPTER 6: 
 
Materials and Methods 
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Mouse Models 
All mice were on a C57/B6 background and were maintained on normal chow 
diets from Laboratory Rodent Diet, Lab Diet 5001. Cre-positive male mice heterozygous 
for Akt1 and Akt2 floxed alleles were bred to females homozygous for Akt1 and Akt2 
floxed alleles. This breeding scheme generated Cre-positive experimental mice 
homozygous floxed for both genes and Cre-negative male mice homozygous floxed for 
both genes that served as controls.  Cre-positive males heterozygous for both floxed 
genes were generated and exhibited a wild type phenotype (data not shown). Adipo-
AKT1 and AKT2 KO mice were on a C57/B6 background. Cre-positive male mice 
homozygous for Akt1 or heterozygous for Akt2 floxed alleles were bred to females 
homozygous for Akt1 or Akt2 floxed alleles. This breeding scheme generated Cre-
positive experimental mice homozygous floxed for both genes and Cre-negative male 
mice homozygous floxed for both genes that served as controls.  Cre-positive males 
heterozygous for Akt2 were generated and exhibited a wild type phenotype (data not 
shown). Adipo-Glut4 KO mice were on a mixed background. Cre-positive male mice 
heterozygous for the Glut4 floxed allele were bred to females heterozygous for the Glut4 
floxed allele. This generated Cre-positive homozygous floxed experimental mice, Cre-
negative homozygous floxed mice and Cre-positive heterozygous floxed mice that 
served as controls. TFKO studs were Cre-positive and homozygoused as the Akt1 allele 
and heterozygous at Akt2 and Foxo1. Dams were homozygous at all alleles and Cre 
negative. Adipo-FoxoAKT2 KO and Adipo-Foxo KO studs were Cre-positive and 
homozygous at both alleles, dams were Cre-negative and homozygous at all alleles. All 
mice were maintained on normal chow diets from Laboratory Rodent Diet, Lab Diet 
5001, except during a 8 week period in November and December 2015 when all mice 
were on a fenbendazole feed due to a pinworm quarantine, Bio-Serv S3867. 
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Macronutrient profiles for Lab Diet 5001 and Bio-Serv S3867 were within 1% point for 
protein, fat, and carbohydrate composition. All mouse experiments were reviewed and 
approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee in accordance with the guidelines of the National Institutes of Health.  
All mice were born at a Mendelian ratio. Tissue samples for genotyping were 
obtained by toe clippings and genotyping was performed using the primers in Table 6-1. 
All mouse experiments were reviewed and approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee in accordance with the guidelines of the 
National Institutes of Health.  
 
Histopathology 
Organs were harvested for histopathology from 12 week old mice, fixed in 
formalin for 24 hours, rinsed in 70% ethanol, and stored in 70% ethanol at 4C overnight. 
Sectioning and staining of the liver, spleen, kidney, and pancreas were performed by the 
Molecular Pathology and Imaging Core at the University of Pennsylvania, supported by 
NIH grants DK050306, CA098101, and DK049210. Sectioning of the epididymal fat pads 
was performed by the Pathology Core at the Children’s Hospital of Philadelphia 
Research Institute. Staining of the epididymal fat pads was performed in house. Slides 
were deparaffinized in xylene (3 x 3 min), then rehydrated in an ethanol series of 100% 
(3 x 3 min), 95% (1 x 3 min), 80% (1 x 3 min), dH2O (1 x 5 min). Slides were stained in 
hematoxylin for 30 minutes, rinsed in dH2O, and rinsed in tap water for 5 min. Slides 
were dipped in acid ethanol 8-12x to destain them, rinsed in tap water (2 x 1 min), and 
rinsed in dH2O (1 x 2 min). Excess water was removed and slides were stained in eosin 
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for 1 min. Slides were then dehydrated in an ethanol series: 95% (3 x 5 min), 100% (3 x 
5 min), and then in xylene (3 x 15 min) before drying and mounting a coverslip.  
 
F4/80 staining 
Rat anti-mouse F4/80 monoclonal antibody C1:A3-1 from AbD Serotec was used 
for staining sections from the epididymal fat for macrophage, natural killer cells, and 
F4/80 positive antigen presenting cell infiltrate (Product Code MCA497A488T). The 
protocol used was modified from that recommended by the supplier. Briefly, sections 
were de-paraffinized in xylene as described above, and rehydrated in alcohol. Sections 
were washed in water. The adipose area was outlined with a PAP pen and sections 
were treated with 0.3% methanol for 15 min to block endogenous peroxidases. Sections 
were washed 3x in TBS. Sections were incubated in normal goat serum for 10 min, the 
species the secondary antibody was raised in. Sections were incubated in a humid 
chamber for 30 min at room temperature. Excess serum was aspirated. The F4/80 
antibody was placed on the sections for 30 min and incubated in a humid chamber, then 
washed 3x in TBS. The HRP-conjugated goat secondary antibody was placed on the 
sections and they were incubated for 30 min in a humid chamber, then washed 3x in 
TBS. Sections were then incubated for 1 hr with the DAB substrate from Vector labs (Cat 
No. SK-4100), as recommended for HRP-conjugated antibodies. Sections were washed 
once with water. No counter-staining was performed for the sections shown in this work. 
Sections were mounted in mounting medium.  
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Adipokines 
 Blood samples were taken from 8-12 week old mice between 12 and 2 pm. 
Adiponectin, leptin, and resistin levels were measured using ELISA kits from Linco 
(mouse adiponectin Cat No. EXMADP-60K, mouse leptin Cat No. EZML-82K, mouse 
resistin Cat No. EZHR-95K) by the Radioimmunoassay and Biomarkers Core at the 
Penn Diabetes Research Center, supported by NIH grant DK19525. 
 
Liver triglyceride 
 Liver triglycerides were measured by weighing 100 mg liver and lysing in 400 uL 
cell lysis buffer (50mM Tris, pH 7.4, 140 mM NaCl, 0.1% Triton-X) (250mg/mL 
homogenate). Samples were diluted 10 fold and incubated in 1% deoxycholate at a 1:1 
ratio for 10 minutes, then incubated for 10 minutes in Thermo-Scientific Infinity 
Triglyceride reagent (Cat No. TR22421). All incubations were performed at 37C. The 
Stanbio triglyceride standard was used. Samples were read on a Tecan plate reader at 
500nm.  
 
Glucose Homeostasis and insulin sensitivity 
 For glucose tolerance tests, 8-12 week old male mice were fasted for 16-18 
hours overnight and injected with 1g/kg glucose intraperitoneally. Blood samples were 
taken from the tail in Sarstedt microvette lithium heparin tubes (Ref 16.433.100) at time 
0 for fasting insulin measurements and 15 minutes post injection. Blood glucose levels 
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were taken from the tail on a OneTouch Ultra glucometer at fasting, and post-injection at 
15, 30, 60, and 120 minutes. 
 For the meal challenges, 8-12 week old male mice were fasted for 16-18 hours 
overnight and then refed normal chow for 2 hours. Blood samples were taken for blood 
glucose, insulin, and FFAs analysis at 0 and 2 hour timepoints. 
For insulin tolerance tests, mice were fasted for 5 hours and injected with 
0.75U/kg insulin. Blood samples were taken from the tail at the 0 minute time point and 
the 30 minute time point for insulin and FFAs measurements.  
 Crystal Chem Ultra-sensitive Mouse Insulin ELISA kits were used for all insulin 
measurements (Cat No. 90080). WAKO NEFA assay kits were used for all NEFA/FFA 
measurements (Cat No. 999-34691, 995-34791, 991-34891, 993-35191).  
 
Immunblotting 
 Immunoblots were performed to verify deletion of AKT1 and AKT2. Akt1 
recombination was verified by isolating adipocytes using Krebs Ringer’s Buffer and 2% 
BSA. Cells were lysed using a RIPA buffer and lysates were passed through an albumin 
column to bind any residual BSA. For Akt2 recombination, whole epididymal fat pads 
were lysed in RIPA buffer. Soluble protein was then denatured in 4x NuPage loading 
buffer and 5% B-mercaptoethanol. Lysates were spun for 10 minutes prior to loading on 
NuPage gels. The same protocol was used for signaling blots, but lysates were made 
from epididymal fat pads from fasted mice, or mice fasted overnight and refed for 2 
hours. The Licor Odyssey system was used for immunblotting. Antibodies were obtained 
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from Cell Signaling Technology, other than p-Perilipin and p-PRAS40, which were 
obtained from Vala Sciences and Millipore, respectively.  Membranes were blocked in 
100% Licor buffer for 1 hour. Primary antibodies were used at a 1:1000 concentration in 
100% Licor buffer + 0.1% Tween-20 and incubated overnight. Membranes were washed 
3x for 10 min in TBS + 0.1% Tween-20. Licor secondary fluorescent antibodies were 
used at a concentration of 1:5000 in 100% Licor buffer from + 0.1% Tween-20 and 
incubated at room temperature for 2 hours. Membranes were then washed 2x for 10 min 
in TBS + 0.1% Tween-20 and 1x for 10 min in TBS without Tween. 10 mLs fresh TBS 
was then used prior to detection on the Odyssey Licor system.  
 
NMR 
 Percent fat mass was determined by the Mouse Phenotyping, Physiology, and 
Metabolic Core, supported by the University of Pennsylvania Diabetes Research Center 
P30-DK19525. 
 
Glucose uptake in isolated adipocytes 
 Adipocytes were isolated and radiolabeled C-14 D-glucose was used as 
previously described (Bae et al., 2003). Briefly, mice were euthanized by CO2 and 
epididymal depots were harvested. The adipose tissue was minced in 3 mLs KRB with 
1% BSA. Ten milligrams of Type I Collagenase from Worthington was added dissolved 
in the buffer. Samples were digested in a shaking water bath at 37 C for ~30 minutes, 
until well-digested. Three milliliters KRB +1% BSA was added. Adipocytes were then 
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filtered through 300um mesh to remove the stromal vascular fraction. Adipocytes were 
then dispersed into eppdendorff tubes containing KRB+1% BSA with the appropriate 
dose of insulin. The volumes were standardized to 450 uL of buffer. Adipocytes were 
pre-treated with insulin in a shaking water bath at 37 C for 15 minutes. Stock solution of 
glucose was made at 100mM concentration. A solution was made with KRP buffer with 
BSA and a 1mM concentration of unlabeled glucose. C-14 glucose from Perkin Elmer 
(Product number NEC042X050UC) was added to the solution at a ratio of 50% the 
volume of the 100mM glucose stock. Ten microliters of the 50x labeled glucose solution 
was then added to the insulin-treated adipocytes an incubation continued for 15 minutes. 
Adipocytes were then washed in ice cold PBS two times and lysed in PBS + 0.5% SDS. 
Three hundred microliters of the lysed sample was added to 3 mLs of scintillation fluid, 
using the the 50x solution for specific activity calculations. The remaining lysate was 
used for protein quantification, to which all the specific activity calculations were 
normalized. 	  
 
Hyperinsulinemic-euglycemic clamp 
 Clamp studies were performed as previously described in Titchenell, et al, 2016, 
with the exception that blood glucose levels were used instead of plasma glucose levels 
(Titchenell et al., 2016). A protocol established by Jason K. Kim was utilized for this work 
(J. K. Kim, 2009). Briefly, mice were anesthetized with pentobarbital and a jugular 
catheter was secured. Mice recovered for 1 week following surgery, when they were 
then fasted for 5 hours prior to the start of the clamp study. The clamp study consisted 
for a constant rate of infusion of insulin at 2.5 mg/kg/min and a glucose infusion rate 
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altered as necessary to maintain blood glucose levels between 100 and 120 mg/dL The 
glucose infusion also contained 3-H glucose at 18 uCi per mouse. Blood glucose levels 
and glucose infusion rates were recorded every 10 minutes and blood samples were 
taken basally and every 20 minutes following the start of the CRIs to determine insulin 
levels. Extra blood was taken at 0 and 100 minutes to determine FFA levels prior to 
insulin and 100 minutes after the start of insulin infusion. At 80 minutes, C-14 labeled 
glucose at 10 uCi per mouse was given to determine glucose uptake into muscle and 
adipose tissues. At 120 minutes, the mice were euthanized by pentobarbital injected into 
the jugular catheter. The rate at which the mice were euthanized was used as a control 
for the patency of the jugular catheter. Mice were dissected and tissues samples were 
taken from adipose depots, skeletal muscle, and liver.  
 Specific activity of the labeled glucose in the blood was calculated by using 10 uL 
of the serum, diluting in 20 uL of dH2O, then adding 25 uL of 0.3 N BaOH and 25 uL 0.3 
N Zn(SO)2. At this point, precipitate was present in the sample. The samples were spun 
for 5 minutes at 12,000 rpm and 25 uL of supernatant was removed and spun dry in a 
drying vacuum. These dry samples were then reconstituted in 100uL of dH2O and then 
diluted in 3mLs scintillation fluid and read on the scintillation counter. For specific activity 
calculations, samples from the labeled glucose used during the clamp for both the basal 
measurements and also during the insulin CRI were handled in the same manner as the 
samples, except that for the labeled glucose given during the CRI, 30uL of sample was 
used, with 60uL of dH2O added and 75uL of BaOH and Zn(SO)2  added.  
 For determination of the tissue specific glucose uptake, approximately 80mg of 
tissue was lysed in dH2O at a ratio of 1mg tissue/10uL dH2O. They were heated for 10 
minutes at 100 C, vortexed briefly, then spun for 5 minutes at 12,000 rpm. 33uL of 
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homogenate was added to scintillation vial as the total sample. 333uL of homogenate 
was then added to a prepped Bio-Rad Poly-Prep prefilled chromatography column with 
AG 1-X8 resin (Cat No. 731-6211.). Columns were washed 3x in 2mLs H2O. 500uLs of 
wash samples were added to scintillation vials to count the quantity of loss. Columns 
were then eluted with 2mLs 0.2M formic acid/0.5M ammonium acetate solution. Eluate 
samples were vortexed and 500uLs was added to scintillation vials. Total, wash, and 
eluate samples were diluted in 3mLs scintillation fluid and counted on the scintillation 
counter.  
 
Transcriptional analysis 
 Whole epididymal fat pads were taken from mice fed ad libitum and lysed in 
Qiazol reagent, then isolated using the Qiagen mRNeasy lipid tissue mini kit (Cat 
No./ID: 74804). The Invitrogen Superscript II reverse transcriptase kit from Thermo 
Fisher was used to reverse transcribe the mRNA to cDNA (Cat No. 18064071). SYBR 
green from Thermo Fisher (Cat No. 4367659) was used in conjunction with the 
specificed primers for qPCR to quantify the mRNA for each gene (Table 6-2).  
 
Statistical analysis 
 T-tests and 2-way ANOVAs, when multiple groups were present, were used to 
calculate significance. All error bars are presented as standard error of the mean.  
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Table 6-1. Primers for genotyping mice 
 Gene Forward Reverse 
Akt2 TGG ACA ATC TGT CTT CAT GCC AC ACC AAC CCC CTT TCA GCA CTT G 
Akt1 GCT CTG ACT AGA CTG TGC AGA G GCT TGA CAG TGT CCA GAG TG 
Glut4 AATATGGCCACGATGGAGAC GGC TGT GCC ATC TTG ATG ACC 
Foxo1 GCT TAG AGC AGA GAT GTT CTC ACA TT CCA GAG TCT TTG TAT CAG GCA AAT AA 
 
Table 6-2. qPCr primers for transcriptional analysis 
 Gene Forward Reverse 
ChREBP CTG GGG ACC TAA ACA GGA GC GAA GCC ACC CTA TAG CTC CC 
ChREBP β TCTGCAGATCGCGTGGAG CTTGTCCCGGCATAGCAAC 
ChREBP α CGACACTCACCCACCTCTTC TTGTTCAGCCGGATCTTGTC 
CGI-58 TGGTGTCCCACATCTACATCA CAGCGTCCATATTCTGTTTCCA 
Elovl6 TCAGCAAAGCACCCGAAC AGCGACCATGTCTTTGTAGGAG 
cd36 ATGGGCTGTGATCGGAACTG TTTGCCACGTCATCTGGGTTT 
Fas GCTGCGGAAACTTCAGGAAAT GAGACGTGTCACTCCTGGACTT 
Srebp1c ACGGAGCCATGGATTGCACATTTG GGA GCC ATG GAT TGC ACA TTT G 
Acly GCCAGCGGGAGCACATC CTTTGCAGGTGCCACTTCATC 
Acaca CGCTCACCAACAGTAAGGTGG GCTTGGCAGGGAGTTCCTC 
Tnfα TGAGGGTCTGGGCCATAGAA GGTGCCTATGTCTCAGCCTCTT 
Rbp4 TCTGTGGACGAGAAGGGTCAT CCAGTTGCTCAGAAGACGGAC 
Nnmt TGTGCAGAAAACGAGATCCTC AGTTCTCCTTTTACAGCACCCA 
Amd-1 AGGGATCTGGGGATCTTCGTA TGCTTGTCAGTCTTTGTCACAC 
Odc-1 TCCTTGATGAAGGCTTTACTGC ACATAGAACGCATCCTTATCGTC 
Sat-1 GAGAACACCCCTTCTACCACT GCCTCTGTAATCACTCATCACGA 
Nampt GCAGAAGCCGAGTTCAACATC TTTTCACGGCATTCAAAGTAGGA 
Glut4 GGC TGT GCC ATC TTG ATG ACC GCCAAGCAGGAGGACGGCAAATAG 
Atgl AACACCAGCATCCAGTTCAA GGTTCAGTAGGCCATTCCTC 
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